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Nanomedicine-based drug delivery aims to improve disease treat-
ment by increasing the targeted accumulation of small-molecule
drugs into diseased tissue while minimising systemic toxicity. Of the
various drug delivery systems available, liposomes have had the most
significant impact in clinical medicine to date, particularly in the field
of anticancer drug delivery, with several products clinically available
[1,2]. Many new liposomal drugs for other diseases (e.g. autoimmune,
cardiovascular) are currently in clinical trials [2], and new exciting ap-
plications are emerging involving their combination with immunother-
apies and radiotherapies [3,4].
In order to develop the best liposomal therapies possible, it is impor-
tant to understand their in vivo behaviour. To achieve this, it is essential
to develop non-invasive imaging techniques that allow us to visualise,
quantify, and monitor their biodistribution over time and, ideally, pro-
vide information regarding drug release. Besides its clear role in the de-
velopment of liposomal therapies, another factor where imaging drug
delivery systems could play an important role in the future is the
individualised prediction of therapeutic efficacy. This is particularly crit-
ical when we consider that the most common mechanism by which li-
posomal nanomedicines accumulate at target tissues (i.e. the
enhanced permeation and retention effect or EPR), is a phenomenon
that is highly heterogeneous in humans [5,6]. This heterogeneity has
been blamed as one of the main factors responsible for the perceived
low efficacy of nanomedicines in humans, compared to preclinical stud-
ies [7]. Thus, non-invasive imaging techniques that identify which
patients or lesions will accumulate high concentrations of the
nanomedicine at the intended target(s) could allow for highly effica-
cious personalised nanomedicinal treatments [8,9].
There are several imaging techniques available to image liposomal
nanomedicines in vivo, each one having advantages and disadvantages
for thispurpose. For example, nanomedicines labelledwithparamagnetic
ions, such as Gd3+ orMn2+, are detectable bymagnetic resonance imag-
ing (MRI) [10]. However, the low sensitivity of MRI (sensitivity defined
here as the amount of label required to be detected by the imaging tech-
nique being discussed), low signal-to-background ratios achievable, and
the dependence of the imaging signal on its microenvironment, makes
whole-body detection and quantification complicated. Ultrasound imag-
ing (US), despite its excellent spatial and temporal resolution, suffers
fromother disadvantages; particularly not allowingwhole-body imaging
and limited tissue imaging depth [11]. Computed tomography (CT) has
been used to image liposomal nanomedicines at the whole-body level
[12], but similarly to MRI, it suffers from low sensitivity and leads to
high radiation doses, particularly when imaging the whole body. Label-
ling liposomal nanomedicines with optical labels such as fluorophores,
allows imaging using techniques such as fluorescence molecular tomog-
raphy (FMT) [13]. This technique allows high sensitivity and quantifiable
in vivobiodistribution studies in animalmodels, butwith limited applica-
tions in the clinical setting due to its low tissue penetration.
Nuclear imaging includes positron emission tomography (PET) and
gamma-emitting techniques such as single-photon emissiontomography (SPECT) and planar scintigraphy. These radionuclide-
based techniques have near-ideal properties to image liposomal
nanomedicines in vivo, in both animals and humans. In comparison
with the previously discussed imaging methods it benefits from high
sensitivity, whole-body capabilities, absence of tissue penetration is-
sues, and accurate quantification. It is particularly important to high-
light the high sensitivity of nuclear techniques in the context of
imaging therapeutic nanomedicines. Thus, unlike modalities commonly
regarded as insensitive such as MRI and CT that require the injection of
gram quantities of contrast agents, nuclear imaging is achieved in
humans with amounts of micrograms or less. As a consequence, imag-
ing with a sub-therapeutic microdose of a liposomal nanomedicine is
possible. This is a significant advantage over other imaging modalities
in the context of facilitating their preclinical drug development and
their potential clinical use in a theranostic approach to predict thera-
peutic efficacy. One limitation of nuclear imaging modalities is that
their spatial resolution is in the range of 1–10mm, depending on the in-
strument and radionuclide used (see Section 2), and is therefore lower
than optical or MR imaging. Although this does not allow the visualisa-
tion of individual nanocarriers or cells, it is sufficient tomeasure the up-
take of nanocarriers in organs and even their distributionwithin organs,
particularly at the human scale.
In order to detect liposomal nanomedicines with nuclear imaging,
these have to be modified by incorporation of a suitable radionuclide
into their structure. In this reviewwe aim to identify and discuss the dif-
ferent radiochemical methods that have been used to date to image and
track the biodistribution of liposomal nanomedicines in vivo, as well as
their applications in bothanimal andhuman studies.Wewillfirst briefly
describe the main characteristics of radionuclide/nuclear imaging that
make these techniques highly suitable for imaging drug delivery sys-
tems in vivo. In the following section we discuss the different choices
ofmethods for radiolabelling and radionuclides, with particular empha-
sis on the stability of the resulting radiolabelled nanomedicines, and the
potential for misinterpretation of results due to in vivo release of the ra-
diolabel. In the last section we will discuss how these radiolabelling
methods and products have been used to date to answer specific ques-
tions regarding the in vivo biodistribution of different liposomal
nanomedicine formulations, their pharmacokinetics, and therapeutic ef-
ficacy indifferentpreclinical diseasemodels, aswell as clinical examples.
Finally, we will draw some conclusions and outline future perspectives
of this exciting area of radionuclide imaging and nanomedicine.
2. Radionuclide imaging
Before we review the different liposome radiolabellingmethods it is
important to be aware of the mechanisms by which nuclear imaging
techniques are able to locate and quantify radionuclides. The imaging
of radionuclides can be performed with two techniques: single-
photon emission computed tomography (SPECT) or positron emission
tomography (PET). By ‘tagging’ or ‘labelling’ compounds with radionu-
clides (radiolabelling), these two techniques can be used to non-
invasively track small molecules, macromolecules and cells inside the
Table 1
Summary of the emission properties, half-lives and common applications of all radionuclides discussed in this review.
Radionuclide Decay mode Half-life Imaging type Common applications
Zr-89 β+ (23%, 0.9 MeV) 78.4 h PET Antibody, cell and nanomedicine labelling
Cu-64 β+ (39%, 0.19 MeV) 12.7 h PET Antibody, nanomedicine and peptide labelling, hypoxia radiotracers
Mn-52 β+ (29.4%, 0.24 MeV) 5.6 d PET Antibody and cell labelling
Ga-68 β+ (89%, 1.899 MeV) 68 min PET Peptide and small molecule labelling
Ga-67 EC 3.3 d SPECT Radionuclide therapy
Tc-99m IT 6 h SPECT Peptide, small molecule and cell labelling, perfusion imaging
In-111 EC 2.8 d SPECT Antibody and cell labelling
Re-186 β- (92%) 3.7 d SPECT Radionuclide therapy
Re-188 β- (100%) 17 h SPECT Radionuclide therapy
I-123 EC 13.2 h SPECT Antibody labelling, thyroid imaging
I-124 β+ (25.6%) 4.2 d PET Antibody labelling, thyroid imaging
I-125 EC 59.4 d SPECT Antibody labelling, thyroid imaging
I-131 β- (100%) 8 d - Radionuclide therapy
F-18 β+ (96%, 0.25 MeV) 109 min PET Small molecule and peptide labelling, bone imaging
Bi-213 β- (97%) 45.6 min - Radionuclide therapy
Ac-225 α 9.9 d - Radionuclide therapy
Y-90 β- (100%) 64 h - Radionuclide therapy
Lu-177 β- (100%) 6.6 d - Radionuclide therapy
Gd-159 β- 18.5 h - Therapy
EC = electron capture; IT = isomeric transition.
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ganisms. Due to the detection of high-energy photons emitted by radio-
nuclides, PET and SPECT have no tissue depth penetration limits and are
alsohighly sensitive (10-10–10-12M) compared to other imagingmodal-
ities such as MRI (10-3–10-5 M). Critically, as briefly mentioned above,
these properties combined mean that imaging can be performed in
humans and other animals, using such small amounts of compounds
that they do not disturb the biological process being observed.
Radionuclides that emit gamma ray photons at defined energy levels
(Table 1) can be imaged using a gamma camera, creating a planar scin-
tigraphic image. SPECT imaging is performed by rotating the camera
around the subject to capture emissions in 3D. To determine the origin
of the photons, collimators are used that exclude diagonally incident
photons (Fig. 1A). PET, on the other hand, relies on radionuclides that
decay by emitting positrons (Table 1, Fig. 1B). These interact with elec-
trons in events known as annihilations that occurwithin a certain range
of the radionuclide, depending on the positron energy (Table 1). This is
known as the positron range, and for commonly-used radionuclides in
PET it can be as low as 0.6 mm for 18F to as high as 2.9 mm for 68Ga,
for example [14]. Each annihilation releases energy in the form of two
511 keV photons, emitted at an angle of approximately 180° from
each other. PET cameras consist of a ring of detectors designed to detect
these annihilation photons and pinpoint the precise origin of the annihi-
lation event along the so-called ‘line of response’ and therefore the ap-
proximate location of the PET radionuclide (Fig. 1B). Because of this
uncertainty about the position of the source of the positron, there is a
fundamental limit to the spatial resolution achievable by PET. Conse-
quently, better images can be obtained from PET radionuclides withFig. 1. Schematic of the detection of radionuclides using (A) single-photon emissionlow positron energy. Furthermore, because PET cameras rely on coinci-
dence detection and do not require collimators, the sensitivity of PET is
superior to that of SPECT [11]. In terms of spatial resolution, that of clin-
ical SPECT scanners (5–12mm) is slightly lower thanwith PET scanners
(3–6 mm), however there is little difference in resolution between pre-
clinical instruments (ca. 1 mm) [15]. PET also provides quantitative im-
ages. Despite this, imaging in the clinic using SPECT is often less costly
and is performed more often than PET, most likely because of wider
availability of SPECT isotopes and radiotracers, particularly those
based on 99mTc (vide infra), and SPECT scanners. There are, however,
an increasing number of PET scanners and radiotracers becoming avail-
able in clinics worldwide, driven by their high sensitivity and spatial
resolution compared to SPECT cameras. A particular advantage of
SPECT over PET is the possibility of imagingmultiple isotopes and there-
fore multiple radioactive compounds within the same subject. This is
due to SPECT radionuclides having unique energy emissions that can
be detected simultaneously and independently. In PET, however, all
photons emitted during positron annihilation have the same 511 keV
energy, making multi-radionuclide imaging not currently possible
with standard scanners. Interestingly, many PET radionuclides also
emit characteristic gamma rays, and it is therefore possible to simulta-
neously detectmultiple PET isotopes with additional gamma-ray detec-
tors by locating triple-coincidence events [16].
The selection of a radionuclide for imaging purposes depends on var-
ious factors. First, it is important to understand the advantages and dis-
advantages of both nuclear imaging techniques as discussed above and
choose one thatwill allow to obtain themaximum information from the
envisaged studies. In clinical situations, if high spatial resolution andcomputed tomography (SPECT) and (B) positron emission tomography (PET).
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choice. In preclinical situations, however, newer SPECT scanners often
outperform PET in terms of spatial resolution. Most importantly, one
should be aware that the half-life of the isotope should be in the same
range as the biological half-life of compound being tracked/imaged.
The labelling method needs to result in a biologically stable radiophar-
maceutical, with a similar activity to the parent molecule in order to
provide truly representative images. This is easier to achieve if the ra-
dionuclide can be attached with the least possible modifications to the
structure of the parent compound. For example, small molecularweight
compounds are often radiolabelled with ‘organic’ radionuclides such as
18F, 11C or radioiodine [17,18] to give radiopharmaceuticals with similar
or even identical chemical structures. Alternatively, molecules can be
radiolabelled using radiometalswhich require a chelator,which is a spe-
cific type of metal-binding molecule that provides stable radiometal
conjugates [19]. The stability of the radiometal-chelator complex is crit-
ical to obtain representative images and therefore the choice of the pair
should be carefully considered [20,21]. An important and often
overlooked aspect is the biodistribution of the ‘free’, or unchelated, ra-
dionuclide (Fig. 2). Once in vivo, release of the radionuclide from the
radiolabelled compounds can occur from metabolic reactions (e.g.Fig. 2.Biodistribution of ‘free’/unchelated radionuclides. (A)Uptake of ‘free’ radionuclides in var
brackets (including 111In [22], 99mTc [23], 18F [24], radioGa [25,26], radioI [27], 64Cu [28,29], 89Z
projections) showing the biodistribution of ‘free’ 99mTc, 64Cu (reprinted with permission fro
et al. [30], Copyright 2011 Elsevier) and 52Mn (reprinted with permission from Graves et a
biodistribution in a prostate cancer patient (reprinted with permission from Piccardo et al. [2
well as in prostate cancer metastases in lymph nodes and bone (white arrows). Lg: lacrimal
heart; L: liver; K: kidney.enzymatic dehalogenation,macrophage degradation) or due to instabil-
ity of the radiocomplex and competition from endogenous metals and
chelators. The subsequent uptake of released radionuclide in tissues/or-
gans, which may be indistinguishable from that of the parent
nanomedicine, may lead to the misinterpretation of data/images.
Based on these considerations, the different radionuclides and various
methods of radiolabelling liposomes will now be explored, defined
into groups, compared, and contrasted.
3. Radiolabelling liposomes
In this review we focus on liposomes [1], as methods and applica-
tions for radiolabelling other nanoparticle-based nanomedicines have
been reviewed elsewhere [33,34]. Our review of the published literature
in this area returned 322 articles with the earliest records from the
early-1970s (see Supplementary Material for methodology).
Technetium-99m (99mTc) has been by a wide margin the most com-
monly used radionuclide to radiolabel liposomes (Fig. 3A), presumably
because of its wide availability, low cost, favourable imaging properties,
and a half-life (6 h, Table 1) that allows imaging for up to 24 h. 111In is
the secondmost-used radionuclide, followed by radioisotopes of iodine.ious tissue/organs, including tumours. The actual chemical form administered is denoted in
r [30], 52Mn [31]); (B) Representative mouse SPECT or PET images (maximum intensity
m Peng et al. [32], Copyright 2006 SNNMI), 89Zr (reprinted with permission from Abou
l. [31], Copyright 2015 ACS). (C) PET maximum intensity projection image of 64CuCl2
9], Copyright 2018 SNNMI). High uptake in the liver and kidneys can be clearly seen, as
glands; Th+Sg: thyroid and salivary glands; St: stomach; Blad: bladder; Tu: tumour; H:
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and particularly 64Cu have been increasingly used (Fig. 3B), reflecting
the growing interest in PET imaging and the increasing availability of
preclinical and clinical PET scanners.
After reviewing all these references, we classified the different lipo-
some radiolabelling methods in the following two main categories
(Fig. 4), based on whether the radionuclide is attached to components
of the lipid bilayer (Fig. 4A), or the intraliposomal space (Fig. 4B).
3.1. Surface labelling
One of the most common methods to radiolabel liposomes is by
inserting radionuclides into the lipid bilayer, otherwise known as surface
labelling (Fig. 4A). Thefirst exampleof thismethodwas reportedbyRich-
ardsonet al.who showed that the surface of a liposomecanbedirectly la-
belled with 99mTc after reduction of 99mTcO4- using stannous chloride
(SnCl2) as a reducing agent [35–39]. To the best of our knowledge,
there are no data on the exact binding site. One possibility is chelation
by the phosphonate groups on the liposome phospholipid surface. Label-
ling efficiencies (LE) of N97% could be achieved after incubating for just
15 min at room temperature. However, labelling with this method was
shown to be unstable in vivo [36,40]. Alternatively, surface labelling can
be achieved by incorporating an appropriate chelator onto the liposome
surface, either attached to the phospholipid or, in the case of long-
circulating liposomes, to the PEGylated phospholipids (Fig. 4A). One of
the earliest examples of this approach was reported by Hnatowich et al.
who labelled liposomes with 67Ga and 99mTc by chelation with
diethylenetriaminepentaacetic acid (DTPA, Fig. 5A) conjugated to
stearylamine, a long-chainhydrocarbon, allowing integration of this lipo-
philic molecule into the lipid-bilayer [41]. Similar subsequent work used
liposomes pre-formulatedwith DTPA conjugated to the phospholipid on
the liposome surface to bind to 99mTc after reduction by stannous chlo-
ride. However, low serum and in vivo stability was observed using
this method [42–44]. Later, Laverman et al. reported an improved
method of radio-labelling PEGylated liposomes containing
hydrazinonicotinic acid (HYNIC, Fig. 5A) conjugated to the lipid
distearoylphosphatidylethanolamine (DSPE). HYNIC is a highly efficient
Tc chelator that, in combination with co-ligands such as tricine
(Fig. 5A), allows radiolabelling with high-specific activities [45]. The la-
belling efficiencywas N95% after 15min incubation at room temperature,
whichmeant that no further purification was required – hence simplify-
ing the labelling procedure. The 99mTc-labelled liposomes showed high
in vitro and in vivo stability [46–49].More recently, Varga et al. developed
a new surface labelling method in which liposomes were formulated
with 2-iminothiolane that could react with the widely used 99mTc-
tricarbonyl complex [50].Whilst the labelling yields (90–95%LE) and sta-
bility are comparable to previous methods, the additional step required
to convert 99mTc-pertechnetate (99mTcO4-) to 99mTc-tricarbonyl (99mTcFig. 3. (A) Research articles published between 1973 and 2018 describing the use of gamma-em
radionuclide, each radionuclide was counted as a separate publication. The total sum of publicat
(265); (B) Research articles published between 1995 and 2018 describing the use of positro
radionuclide, each radionuclidewas counted as a separate publication. The total sumof publicatio(CO)3+) couldbe seen asneedlessly complex compared to othermethods,
particularly for human imaging studies. Several studies have since
revisited using DTPA-conjugated liposomes radiolabelled with 99mTc;
DTPA was either conjugated to the phospholipid, DSPE [51], PEGylated
DSPE [52], or to cholesterol during formulation of the liposomes [53].
Despite the high number of studies using 99mTc for liposome track-
ing, it is worth nothing that its relatively short half-life (t1/2 = 6 h,
Table 1) can limit its use in tracking liposomes to approximately 24 h
post-administration. To overcome this limitation, particularly for long-
circulating liposomes that exploit the EPR effect such as those used for
cancer/inflammation therapy (vide infra), other studies have focused
on surface labelling with DTPA using the longer-lived SPECT isotope
111In (t1/2=2.8 d). Thiswasfirst described by Elbayoumi et al., however
the required purification step by overnight dialysis is a serious limita-
tion to their method [54], which could be overcome nowadays by
using faster size-exclusion techniques such as those based on centrifu-
gal filters. Other methods involved the use of non-radioactive indium
metal in the radiolabelling procedure to saturate the DTPA chelators
on the liposomal surface [55–57]. However, several reports have
shown that LE of N95% can be achieved simply by incubating 111In
with these formulations at 25–37 °C for up to 1 h [58–61]. Interestingly,
a direct comparison of the radiolabelling of DTPA-functionalised
PEGylated liposomes with both 99mTc (using both 99mTcO4- and 99mTc
(CO)3+) and 111In was reported by Helbok et al. [58]. Labelling efficien-
cies of N95% were achieved with 111In over a wide liposome concentra-
tion range. Labelling over the same concentration range was possible
with 99mTcO4- , however the LE was consistently lower (74.9 ± 6.2%),
whereas for 99mTc-carbonyl N80% LE was achievable but only with 50-
fold more liposomes. Despite this, serum stabilities after 24 h for 111In
and 99mTc-carbonyl were comparable and their ex-vivo biodistribution
in Lewis rats similar over 12 h. Uptake in the kidneys after 12 h was
more than 2-fold higher for 99mTc-carbonyl-DTPA liposomes compared
to 111In-labelled liposomes [58], suggesting the potential release of the
radionuclide in a hydrophilic form. The authors also demonstrated
radiolabelling with 68Ga and the therapeutic isotope 177Lu using the
same formulation; achieving N95% LE for 68Ga-DTPA and N80% LE for
177Lu-DTPA, albeit using a 5-fold higher concentration of NP [58]. Sur-
face labelling using DTPA has also been reported for the therapeutic ra-
dionuclides yttrium-90 [62], and holmium-166 [63].
More recently, reports have started to focus on surface labelling
using chelators for PET radiometals. Malinge et al. used 1,4,7-
triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA, Fig. 5A) at-
tached to PEGylated lipids to labelmagnetic liposomeswith 68Ga,which
could be purified with a magnetic column, however it is unclear if the
use of such a short-lived isotopewas justified in this context [64]. Label-
ling using 64Cu has been an increasingly popular choice, because its half-
life allows tracking liposomes for up to ca. 48 h. Seo et al. were the first
to describe a reliablemethod for the attachment of 64Cu to the surface ofitting and therapeutic radionuclides for liposome labelling. For articles using more than one
ions in the graph (300) is therefore superior to the actual number of unique articles found
n-emitting radionuclides (PET) for liposome labelling. For articles using more than one
ns in the graph (67) is therefore superior to the actual number of unique articles found (59).
Fig. 4. Schematic illustration of the different methods for radiolabelling liposomes. (A) Surface radiolabelling: the radionuclide, with or without a chelator, can be linked to the liposomal
membrane via a PEG chain or incorporated directly into the lipid bilayer. (B) Intraliposomal radiolabelling: the radionuclide is encapsulated within the aqueous core. Ionophores can be
used to transport radionuclides across the bilayerwhere they can be bound by chelators or drugs inside the liposomes, or radioactive compounds/complexes can passively cross the bilayer
and become trapped.
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64Cu-specific chelator, 6-[p-(bromoacetamido)benzyl]-1,4,8,11-
tetraazacyclotetradecane-N,N′,N′′,N′′′-tetraacetic acid (BAT, Fig. 5A).
When inserted into the liposomal surface, this platform allowed LE of
N80% after incubation at room temperature for 1 h, with N90% of the ra-
diation still bound after incubation with mouse serum for 48 h. Ex vivo
biodistribution 48 h after administration showed high splenic uptake
of the liposomes compared to 64CuCl2 and the 64Cu-PEG-lipid suggest-
ing in vivo stability of the formulation. Interestingly, the authors also
showed 64Cu-PEG-lipid uptake in the liver was roughly 3-fold higher
than the liposomes [65]. This uptake of radiolabelled lipids should be
carefully considered when tracking liposomes as release of these struc-
turesmay occur after uptake in tissues and subsequent destruction of li-
posomes. Additional work by Seo and collaborators looked at labelling
by attaching 64Cu complexes of 1,4,8,11-tetraazacyclotetradecane-
1,4,8,11-tetraacetic acid (TETA, Fig. 5A) and 4,11-bis(carboxymethyl)-
1,4,8,11-tetraazabicyclo-(6.6.2)hexadecane (CB-TE2A, Fig. 5A)
conjugatedwith 2-pyridyldithiol groups tomaleimide functionalised li-
posomes [70]. After complexation with the radionuclide the complexes
were activated using tris(2-carboxylethyl)phosphine (TCEP) to give the
free thiol group, whichwould in turn allow binding to the liposome sur-
face. Optimised conditions allowed N90% LE with N84% stability in
mouse serum after 48 h. However, quenchingwith ethanethiol was per-
formed first in lieu of having thiol reactive groups covering the liposomesurface, which would likely affect the biodistribution. Intriguingly, the
authors showed that attaching the complex to either PEG or non-
PEGylated lipids altered the biodistribution, with 5% higher hepato-
splenic uptake occurring after 48 h [70]. This work shows that the
biodistribution of radiolabelled liposomes can easily be altered solely
based on the position of the radiocomplex, which could be viewed as
a drawback to surface labelling of liposomes. This method was also
used to show that simply using DPPE, i.e. shortening the carbon chain
length of the maleimide lipid by two units, caused a severe reduction
in stability, with blood clearance decreasing from 18 h to 5 h [71].
Work from other groups has focused on using DOTA (Fig. 5A) conju-
gated lipids for 64Cu labelling [72–75]. Labelling efficiencies of 76–99%
have been reported after incubation with mild heating (37–50 °C),
with serum stability N95% after 24 h [73,74]. Jensen et al. compared
surface-bound DOTA radiolabelled with 64Cu and the longer-lived iso-
tope 52Mn [75]. 52Mn-DOTA liposomes were shown to have a shorter
blood half-life, although this was not significant. Additionally, urinary
bladder uptake was higher for 52Mn-DOTA liposomes for all timepoints
after 40min suggesting the 52Mn complex was less stable. Luo et al. de-
scribed a method of radiolabelling porphyrin-phospholipid liposomes
with 64Cu, in which the radionuclide was able to bind to the porphyrin
chelator within the lipid bilayer [76]. Radiolabelling was shown to be
dependent on the presence of the porphyrin, with low labelling effi-
ciency (b20% LE after 4 h). Other groups have focused on surface
Fig. 5. Schematic showing the chemical structures of various compounds used to assist the radiolabelling of liposomes, all of which are discussed in this review. (A) Structures of metal
chelators that are either attached to the lipid surface or encapsulated inside the liposomal core, or (B) radiolabelled amphiphilic probes can be inserted into the lipid bilayer for
radiolabelling. (C) Alternatively, ionophores can used to transport radionuclides inside the liposomal core and release the isotopes where they can either be trapped by binding to
entrapped chelators or in some cases can bind directly to (D) the chelating groups of encapsulated drugs. (E) Radiolabelling can be also achieved by the remote loading of metal
complexes or radio-iodinated compounds that become trapped in the liposomal core via protonation of the ligand used.
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a better match for long-circulating PEGylated liposomes. It was previ-
ously shown by Abou et al. that chelator-free labelling with 89Zr was
possible via binding of the radionuclide directly to the lipid phosphate
head groups, however, this interaction was shown to be weak, contrib-
uting to low serum and in vivo stability [77]. To overcome this, several
groups have performed surface labelling with 89Zr using
desferrioxamine (DFO, Fig. 5A) as a chelator [78–82], which allows
radiolabelling at neutral pH with only mild heating. Pérez-Medina and
collaborators reported and compared two radiolabelling methods
using this ligand; DFO was either attached directly to the surface and
then radiolabelled, or the radio-complex synthesised and then attached
to the liposomes using click-chemistry [78]. Using surface-bound DFO
was shown to be superior to the latter method, with shorter
radiolabelling times (4 h and 16 h, respectively), higher serum stability
after 24 h (90% and 83%, respectively) andmore favourable in vivoprop-
erties. The circulation time of the click-labelled liposomes was severely
reducedwith a blood half-life of 1.2 h, compared to 7.2 h for the surface-
DFO liposomes, which the authors stated was due to higher tendency of
the liposomes to aggregate. This resulted in higher clearance through
the reticuloendothelial system (RES) and therefore lower overall tu-
mour uptake of this formulation. Hence, only the surface-DFO labelling
technique was used in later studies [79,80]. Seo et al. compared the ef-
fect of increasing PEG-length between the liposomal surface and the
89Zr-DFO complex [81]. They synthesised three formulations with DFO
either bound directly to the lipid or with a 1K or 2K PEG spacer which
showed no significant differences in terms of %LE, serum stability orblood half-life. However, image-based analysis showed significantly
higher tumour uptake and retention over 168 h when using a 2K PEG
spacer, as well as significantly higher liver and spleen uptake from 48
to 168 h compared to the other two formulations (Fig. 6A). This again
highlights how small modifications in chelator position within the sur-
face of radiolabelled liposomes can affect their biodistribution and
pharmacokinetics.
The othermajor approach for surface labelling of liposomes involves
non-metallic radionuclides covalently bound to both PEGylated/non-
PEGylated lipids (Fig. 4A). Radiolabelling without the use of often
bulky chelators can be beneficial, as this can affect the biodistribution
of the liposomes as previously discussed. A small set of studies has
looked at using radioisotopes of iodine with half-lives compatible with
liposome tracking (Table 1). Kao et al. reported 131I-radiolabelled mi-
celles [83], and two reports looked at using 125I for the tracking of lipo-
somes conjugated with monoclonal antibodies. In both cases, the
radioiodine was bound to the antibody attached to the surface, with
the liposomes additionally radiolabelled using an internalised 99mTc
complex [84] or a surface-bound 111In-DTPA complex [61]. Other
work has focused on surface labelling using the shorter-lived PET radio-
nuclide 18F. Several groups have described 18F-based surface labelling
using 3-[18F]fluoro-1,2-dipalmitoylglycerol ([18F]FDP, Fig. 5B) [85–88].
The precursor containing a reactive tosyl leaving group could be reacted
with K[18F]F/Kryptofix to give [18F]FDP within 20 min at 100°C, which
was then mixed with a lipid formulation during liposomal preparation.
Radiolabelled long-circulating liposomes could be prepared in just over
an hour with a decay-corrected radiochemical yield of 70%. In vivo
Fig. 6. Small differences in the radiolabelling method can affect the biodistribution of liposomes. (A) Significantly higher EPR-mediated tumour and liver uptake and retention observed
when using longer PEG chain lengths between the 89Zr chelator (DFO) and the liposomal surface (shortest on top, longest at the bottom). (B) Significantly higher liver uptake observed
over time for liposomes labelled on the surface with 111In-DTPA (top row) compared to intraliposomally labelled liposomes using oxine and encapsulated DTPA (bottom row). EPR-
mediated uptake in the infected tissue was not significantly different. Figures adapted with permission from (A) Seo et al. [81] and (B) Van der Geest et al. [60], Copyright 2015 Elsevier.
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able bone uptake (a consequence of defluorination), at least within the
timeframe of the imaging study (90min) [85]. Similarly, Jensen et al. de-
scribed a method using a radiolabelled cholesteryl ether [89]. After at-
tachment of 18F, the compound was added during the formation of the
liposomes resulting in N95% incorporation. An alternative method was
reported by Urakami et al. using the amphiphilic probe, 1-[18F]fluoro-
3,6-dioxatetracosane ([18F]SteP2, Fig. 5B) [90–93]. Once synthesised,
preformed liposomes could be radiolabelled using a solid phase transi-
tion method wherein the PET probe was transferred to a glass vial,
and the solvent removed, the liposomes were added with agitation
allowing the long alkyl chain to intercalate with the lipid bilayer on
the liposome surface. This technique allowed both a labelling efficiency
and stability in serum (after 30min) of N80% [90] and the ability to label
preformulated liposomes is very beneficial. Considering that liposomes
and similar compounds in the nanometre scale tend to have long bio-
logical half-lives, it is easy to dismiss the use of 18F based on its short
half-life, however it may be beneficial in applications where long-term
tracking is not needed. This could include, for example, fast liposome
trafficking to the brain [91–93] or accumulation in the heart [86,87]
within an hour of administration. Another interesting example of this
approach was reported by Rösch and collaborators, using 18F-
radiolabelling to test the effect of linear and branched lipids on liposome
distribution within the first hour after administration [94,95]. The lipids
were radiolabelled via the copper-catalysed azide−alkyne cycloaddi-
tion reaction (CuAAC) between alkyne-functionalized lipids and a
18F-labelled azide compound and then added during synthesis of the
liposomes. In vivo tracking of liposomes using this method was able to
elucidate vast differences in biodistribution and accumulation within
the first hour. Whilst maybe not applicable for longitudinal imaging of
liposomes, labelling and tracking with 18F may be a valuable tool in
the development of new formulations.
3.2. Intraliposomal labelling
As alternatives to radiolabelling the surface of a liposome, there are
various methods to incorporate and trap radionuclides inside the lipo-
somal core (Fig. 4B). This approach, in principle, should benefit from im-
proved in vivo stability due to the protective effect of the lipid bilayerthat prevents interaction between the radionuclide and the extra lipo-
somal biological components (e.g. blood proteins, etc). In addition, the
lack of surface modifications should result in identical physicochemical
properties compared to the starting liposome. Some of the earliest stud-
ies performing the radiolabelling of liposomes achieved this by simply
encapsulating a radiometal complex with DTPA inside the liposomal
core during formation of the liposomes. This was first done with 99mTc
[96–99], and later 111In [100] and 159Gd-DTPA [101] – as well as with
the therapeutic isotope 225Ac by encapsulating the DOTA complex
[102]. Alternatively, encapsulated drugs could themselves be labelled
with radioiodine [56,103–109] or 18F [110] before liposomal formula-
tion andmore recently liposomeswere radiolabelled by being prepared
in the presence of [18F]FDG [111–114].Much like the surface-labelled li-
posomes that are radiolabelled during liposomal formulation, these
techniques can be limited due to the longer, more complicated
radiosynthesis needed (especially when using short-lived isotopes) as
well as the inability to label preformed liposomes. However, the ability
to directly label the drug inside the liposomes and track its distribution
is clearly valuable and will be discussed further in Section 3.2.3 (vide
infra). The following sectionswill focus on intraliposomal labelling tech-
niques that allow the radiolabelling of pre-formed liposomes either
with or without modification.
3.2.1. Ionophore-chelator binding
Themost common form of intraliposomal labelling is often achieved
via the use of ionophores, which are molecules that allow the transport
of metal ions (in this case radiometals) across lipid bilayers – often in
the form of a neutral, lipophilic complex. Due to the metastable nature
of these complexes, the radiometal can then be released inside the lipo-
somes and bind to an entrapped chelator, forming a stable complex
within the liposomal core (Fig. 4B). The first example of this was re-
ported by Gamble and collaborators who embedded the calcium iono-
phore A23187 (Fig. 5C) into the lipid bilayer of liposomes, allowing
transport of 111In inside the liposomal corewhere itwas chelated by en-
capsulated nitrilotriacetic acid (NTA, Fig. 5A) allowing N90% LE
[115,116]. Hwang et al. later reported several methods that did not re-
quire pre-formulating liposomes to incorporate an ionophore in the bi-
layer: 111In could be transported into NTA-containing liposomes by
small molecular weight ionophores, 8-hydroxyquinoline (oxine,
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(Fig. 5C) [120]. Additionally, Utkhede et al. later showed that DTPA-
containing liposomes could be labelled by reacting 90Y with A23187,
allowing transport of the complex across the bilayer [121]. Oxine was
later used by Gabizon et al. to label liposomes encapsulating the chela-
tor DFO with 67Ga [122,123], showing that when using tropolone as
an ionophore the LE was threefold lower than with oxine. This tech-
nique using DFO was later adapted by Boerman et al. using 111In
[124,125]. Similarly, Harrington and collaborators reported using
111In-oxine to radiolabel liposomes containing DTPA, which allowed
N90% LE after 15 min incubation and high serum stability for up to 10
days [126–128]. The biodistribution of the radiolabelled liposomes
with 111In-DTPA showed the long circulating properties of the
PEGylated nanoparticles with high amounts of activity in the blood up
to 24 h, followed by hepato-splenic uptake after that time – whereas
111In-DTPA was cleared rapidly [127]. Boerman et al. later showed
that this labelling method was compatible with using an encapsulated
drug. PEGylated liposomal prednisolone [129] and liposome encapsu-
lated superoxide dismutase [100,130] could still be radiolabelled with
N85% LE, albeit with a longer incubation timewith 111In-oxine than pre-
viously reported. This method was later used to label liposomes with
177Lu byWang et al. [131]. Van der Geest et al. later compared this label-
ling technique with surface labelling with 111In using DTPA-DSPE lipo-
somes – the labelling of empty liposomes (without DTPA) was also
reported [60]. Labelling efficiencies N95% were reported using both
radiolabellingmethods, as well N95% serum stability after 48 h,whereas
the empty liposomes showed lower LE (62%) and serum stability (68 %).
A DTPA challenge assay showed that the surface-labelled liposomes had
a higher stability than oxine-DTPA and empty liposomes (93%, 46% and
2% respectively) after incubation with 10-3 M DTPA for 24 h. Interest-
ingly, when assessing the in vivo distribution of the formulations in
mice, the surface-labelled liposomes showed significantly higher liver
uptake over 72 h – compared to the oxine-DTPA liposomes – whereas
no difference was seen in spleen or the target abscess uptake (Fig. 6B)
[60]. This may indicate that release of 111In-DTPA from inside the lipo-
somes is occurring, suggesting lower in vivo stability, as 111In-DTPA is
rapidly cleared [127], whereas 111In-DTPA-DPSE (released from lipo-
somes during degradation) will likely accumulate in the liver.
The first use of this labelling strategy with a PET radionuclide was
developed by Petersen et al. [132,133], and later used by Locke et al.
[134], who used the ionophore 2-hydroxyquinoline (2HQ, Fig. 5C) to
transport 64Cu across the liposomal bilayer where it can be trans-
chelated with encapsulated DOTA. Labelling efficiencies N95% could be
achieved after incubating the DOTA liposomes with the ionophore-
complex for up to 1 h at temperatures between 20–50°C, with N99%
serum stability after 24 h. The in vivo stability was shown via the long
circulation time of 64Cu-liposomes compared to the free 64Cu-DOTA
complex, which was cleared rapidly. The work also highlighted the
intraliposomal pH as a key consideration when using this technique. Li-
posome loading in this instance was N95% and 70% for pH 4 and 5.9 re-
spectively, suggesting the complexation by DOTA was affected [132].
This conceptwas explored further by Jensen et al. whoused oxinederiv-
atives to load 52Mn into DOTA encapsulated liposomes [75]. Labelling
efficiencies above 90% could be achieved when using oxine and 5,7-
dichloro-8-hydroxyquinoline (8HQ-2Cl, Fig. 5C) after incubation at
55°C with an intraliposomal pH 4, but increasing the pH to 7.8 led to a
large reduction in labelling using oxine (ca. 30–70% LE) whereas this
was not observed for 8HQ-2Cl. Therefore, the internal pH will not only
affect the chelation by the internalised ligand, but also the dissociation
of the ionophore complex used. The authors also compared liposomes
labelled with ionophores to those labelled using surface-bound DOTA.
The intraliposomally labelled 52Mn-liposomes showed a significantly
higher blood half-life and lower urine activity was observed 5 h after
administration, suggesting higher stability than the surface-labelled
counterpart [75]. The use of oxine, as well as A23187, to radiolabel
DOTA-containing liposomes was also reported by Sofou andcollaborators with 225Ac [135,136]. Further work using ionophore-to-
chelator labelling was reported by Li et al. who used oxine and 2HQ
with 89Zr to label liposomes encapsulating DFO [137]. Labelling efficien-
cies of N95% and 83% were achieved using oxine and 2HQ respectively,
with 94% stability inmouse serum after 48 h. Despite this, the in vivo in-
stability of the 89Zr labelled liposomes was demonstrated by large bone
uptake observed both 24 h and 48 h after administration, with little
spleen or liver accumulation.
3.2.2. Unassisted loading
Theuse of a chelator to transport a radiometal across the lipid bilayer
of liposomesmay not always be necessary. In the specific case of 64Cu2+,
Henriksen et al. showed that simply incorporating a DOTA chelator in-
side of a variety of liposomal formulations was sufficient to achieve la-
belling efficiencies of over 90% in only 30 min [138–141]. This
‘unassisted loading’ (Fig. 4B) of the radionuclide occurs due to depletion
of intraliposomal non-radioactive copper by the DOTA chelator. A steep
copper gradient is established across the membrane, causing diffusion
of 64Cu2+ into the liposome where it is trapped upon chelation by the
DOTA ligand. Not only does this technique increase the simplicity of
radiolabelling liposomes, but it removes the need for ionophores,
which are known to have a variety of biological activities [142]. Lipo-
some labelling in this manner was found to be temperature-
dependent with mild heating to 55°C needed to ensure efficient
radiolabelling compared to the ionophore-assisted loading (IAL),
which was temperature-independent. Therefore, the labelling of more
temperature-sensitive liposomal formulations may be limited with
this technique. Additionally, the need for pre-formulating liposomes
with a chelator may again limit its use with liposomal nanomedicines
already on themarket. However, the usefulness of this technique for in-
vestigating new formulations and the in vivo distribution should not be
downplayed.
3.2.3. Ionophore-drug binding
Building on the previous work using radio-ionophore complexes,
our group developed a facile method for the radiolabelling of liposomal
formulations without the need for incorporated chelators and therefore
without having to chemically modify the formulation [143–145]. This is
based on the metal-chelating properties of certain drugs (Fig. 5D) that
are able to bind the radionuclide after ionophore-mediated transport
across the lipid bilayer (Fig. 4B). For example, complexes of doxorubicin
with manganese have been previously reported [146,147]. High
radiolabelling yields of Doxil® and pre-formed PEGylated liposomal
alendronate (PLA) were easily achieved with the PET radionuclides
89Zr and 52Mn using oxine as an ionophore. The radiolabelling of the
same formulations was also carried with 64Cu using 2HQ, however,
quantitative labelling was only seen with PLA and only at higher drug
concentrations. Since 2HQ has been established as a good ionophore
for copper [132], this difference in radiolabelling is likely due to weaker
drug-metal binding. Hence, the extent of radiolabelling using this
method will always be limited by the interaction between the
radiometal and the drug inside the liposomal formulation.
The in vivo stability of the 89Zr-labelled PLA was demonstrated by
the tracking of the liposomes within a metastatic breast cancer model,
showing EPR-driven uptake in primary tumour and metastatic organs
(lymph nodes and lungs) (Fig. 7A,B) [143]. The long-circulating proper-
ties of the liposomes were confirmed by a decrease in heart uptake over
72 h, which was contrasted with an increase in spleen uptake (Fig. 7C).
Similarly, 52Mn-labelled Doxil® was shown to be stable in the blood
pool for up to 24 h, however, imaging 72 h after administration and
ex vivo biodistribution showed a profile similar to that of non-chelated
52Mn with high uptake in the pancreas, salivary glands and kidneys ob-
served (Fig. 7D) [144]. These results suggest that following uptake in the
reticulo-endothelial system (RES), the subsequent destruction of the li-
posomes led to the release of the drug cargo and the radionuclide. In-
deed, when using 89Zr-PLA, uptake in the femur due to release of ‘free
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the radionuclide demonstrates the need for cautionwhen analysing im-
ages of radiolabelled nanomedicines. In particular, radioactive isotopes
of endogenous metals, such as 52Mn and 64Cu, may bemore susceptible
to trafficking out of the tissues and into the bloodstream, resulting in
secondary uptake in other organs. Specifically, in the case of 64Cu and
52Mn it may be difficult to separate free radiometal distribution from
that of liposomal uptake in the liver and even in tumours (Fig. 2)
[28,31]. This is less of an issue when labelling with 89Zr (a non-
endogenous metal), which almost exclusively shows uptake in the
bone [30].
3.2.4. Remote loading
Finally, the labelling of pre-formed liposomes can also be achieved
by the remote loading of metal complexes or radiopharmaceuticals
inside the liposomal core (Fig. 4B). The first example of this was re-
ported by Rudolph and collaborators who used 99mTc-labelled
hexamethylpropyleneamine oxime (HMPAO, Fig. 5E) to radiolabel
pre-formed liposomes encapsulating albumin or haemoglobin along
with glutathione [148,149]. It was found that glutathionewas necessary
to allow N90% LE, whereas liposomes encapsulated solely with albuminFig. 7. Ionophore-drug binding radiolabelling of liposomes. (A) Coronal and sagittal PET-CT ima
at the tumours of the same animal from 1 h to 72 h after injection of 89Zr-PLA showing the incre
decreasing uptake in blood pool/heart (H); (B) Coronal and sagittal PET-CT images centred at th
PLA in metastatic lymph node (LNmet) and lungs (Lumet); (C) Time-activity curves (89Zr-PLA) fr
injected with [52Mn]Mn-DOXIL at 1, 24 and 72 h post-injection, and showing increasing uptak
thus suggesting Doxil cargo release (see Fig. 2). CA=carotid arteries; h=heart; DA=descend
Edmonds et al. [143], Copyright 2016 ACS.or haemoglobin had 11% and 19% LE, respectively. The authors demon-
strated that the complexwas trapped inside the aqueous liposome core,
where it was postulated the complex would undergo reduction by in-
teraction with glutathione, allowing trapping of the agent. This interac-
tion had previously been proposed as themechanism for the trapping of
99mTc-HMPAO in the brain [150]. Cao et al. reported a similar method
using 99mTc-labelled diisopropyl iminodiacetic acid (99mTc-DISIDA,
Fig. 5E), again showing that liposomes containing glutathione resulted
in higher uptake in the aqueous core [151]. Laverman et al. later com-
pared HMPAO labelling with the use of HYNIC bound to the liposome
surface [46]. Whilst there was no difference in serum stability after 48
h, the surface-labelled liposomes showed higher stability after incuba-
tion with DTPA, cysteine or glutathione. In vivo tracking showed that
kidney uptake was 3-fold higher after 24 h for HMPAO-labelled lipo-
somes, suggesting lower stability as 99mTc-HMPAO is known to be
renally excreted. However, it was also noted by the authors that the
radiolabelled HYNIC-phospholipids would likely accumulate in the
liver after degradation. This may make it difficult to elucidate liposomal
signal in the liver, whereas in the case of HMPAO liposomes, renal up-
take would avoid this issue. While both methods are simple, the need
for modification of the liposomes, either by encapsulating glutathioneges in the 3E.Δ.NT/NSGmousemodel of metastatic breast cancer [143]. Images are centred
asing uptake over time in the primary tumour (T), spleen (Sp), liver (L) and bone (B), and
e LNmet of same animal fromA at 72 h after injection of 89Zr-PLA, showing uptake of 89Zr-
om the study shown in A. (D) In vivo PET-CT imaging (MIPs) in a healthy B6CBAF1 mouse
e in kidneys/pancreas and salivary glands after 24 h, characteristic of free manganese, and
ing aorta; K=kidneys; SG= salivary glands; P=pancreas. Adaptedwith permission from
144 F. Man et al. / Advanced Drug Delivery Reviews 143 (2019) 134–160or integrating HYNIC onto the surface, is a limitation of these methods
for labelling nanomedicines.
Bao and collaborators developed an alternative remote-loading
method using the chelator N,N-bis(2-mercaptoethyl)-N’,N’-diethyl-
ethylenediamine (BMEDA, Fig. 5E) for 99mTc [152,153], and later 186Re
[154]. The neutrally charged complex allowed uptake into the aqueous
liposomal core where it is protonated and becomes trapped in a more
hydrophilic form. Initially it was shown that uptake of the 99mTc com-
plex into liposomes containing glutathione was moderate (ca. 37% LE),
but with increased stability (N80%) in serum up to 72 h compared to
empty liposomes (b35% stability) [152]. However, a subsequent study
showed that the presence of glutathione resulted in lower stability com-
pared to liposomes simply loadedwith ammonium sulfate or citrate, ir-
respective of surface charge. In all cases, an improved LE was observed
ranging from 66 to 84% [153]. The main advantage of this method is
the ability to label preformulated liposomal nanomedicines without
modification, as demonstrated by the use of this method for labelling
and tracking of Doxil® both with 99mTc- [155] and 186Re- BMEDA
[156]. This technique was later used by other groups for loading the
therapeutic radionuclide 188Re into liposomes to form a theranostic
platform [157–160].
The limitations in the use of a relatively short-lived radionuclide, as
well as those with using SPECT, were eventually overcome by Lee et al.
who developed a 64Cu complex capable of labelling liposome
nanomedicines without modification [161–164]. The 64Cu complex of
diacetyl 4,4′-bis(3-(N,N-diethylamino)propyl)thiosemicarbazone (4-
DEAP-ATSC, Fig. 5E) could be formed in just 1 min at room temperature
with N94% RCY. 64Cu-4-DEAP-ATSC allowed N90% LE after 10 min at
65°C of two formulations of liposomal doxorubicin [161], as well as
empty liposomes [162,164], indicating the labelling/trapping was not
dependent on the presence of a encapsulated drug. Similarly to
BMEDA, the neutral lipophilic complex becomes doubly protonated
and charged, allowing it to be trapped in its hydrophilic form. The
radiolabelled doxorubicin formulations showed high in vitro stability
in serum (N99% after 48 h) and in vivo stability at 24 h. Ex vivo
biodistribution showed higher splenic uptake of radiolabelled targeted
doxorubicin liposomes compared to 64Cu-complex 24 h after adminis-
tration, however, both radiopharmaceuticals showed similar uptake in
the liver and kidneys. This is likely due to release of free 64Cu, as it is
known that copper-bisthiosemicarbazone complexes are not stable in
vivo [165]. Thus, any 64Cu-4-DEAP-ATSC released from the liposome
will decompose and release free 64Cu. This is consistent with the obser-
vation from the authors showing that both the 64Cu-4-DEAP-ATSC and
‘free 64Cu’ had similar pharmacokinetics. Thus, this distribution of cop-
per after release of the complex due to destruction of the liposomes
should be taken into account, especially as 64Cu in its free form or as
part of a bisthiosemicarbazone complex, is known to accumulate in tu-
mours at similar levels (Fig. 2) [165,166]. Indeed the authors showed ca.
3 %ID/g tumour uptake of 64Cu-4-DEAP-ATSC 24 h after administration
[161].
Most recently, Engudar et al. reported a novel radiolabellingmethod
using a radioiodinated compound, amino diatrizoic acid (ADA, Fig. 5E),
which could be loaded into liposomes using a transmembrane pH gradi-
ent [167]. 125I-ADA and 124I-ADA could be prepared with radiochemical
yields of up to 64% and 55%, respectively, with radiochemical purities
N90%, albeit after a lengthy purification process. The agents could be in-
corporated into liposomes after increasing the external pH to 7, the
unprotonated compound then passively crossing the bilayer to become
protonated and trapped inside. The maximum LE achieved labelling
with 124I-ADA was 86% after 6 h of stirring at 55°C, though N70% LE
could be achieved after just 2 h, with labelled liposomes shown to be
98% stable in HEPES buffer after 168 h. 124I-labelled liposomes showed
long circulating properties with a blood t1//2 = 19.7 h compared to
124I-ADA which was rapidly cleared after just a few hours. Low
deiodination of the liposomes occurred, evidenced by just 1 %ID/g of
the radioactivity in thyroid present after 72 h. However, the authorsnote that free 124I-ADA may be released after uptake in organs and tu-
mours, after which it will be rapidly cleared. This may lead to a biasing
of the blood half-life and also organ uptake over time [167].
In summary, the radiolabelling of a liposomal nanomedicine should
not be treated as a ‘black box’. Every aspect of radiolabelling, from the
radionuclide and chelator choice to the location of the radiolabel incor-
poration, can have effects on the pharmacokinetics and biodistribution
of the nanomedicine observed in vivo. As a result, the radiolabelling
method should be carefully chosen based on the purpose of the study
being performed. The biodistribution of the ‘free’ radionuclides,
radiometal complexes/radiolabelled compounds and radiometal
complex-lipid conjugates/amphiphilic probes should also be considered
– depending on the method used – as each may be released following
destruction of the liposomes and will potentially complicate the analy-
sis of the images.
4. Applications of radiolabelled liposomes
As mentioned previously, radiolabelled liposomes have had numer-
ous applications, covering in vitro, preclinical and clinical studies. As we
recently reviewed clinical studies using radiolabelled nanomedicines
[9], this section will mostly focus on preclinical studies, with an empha-
sis on developments in the last 10-15 years. Most studies are in the field
of oncology, however radiolabelled liposomes have also beenused in in-
flammation, infection, cardiovascular diseases, dermatology and other
diseases.
4.1. Formulation
The pharmacokinetic properties of liposomes can be modified by
changes in their size, chemical composition of the lipid bilayer, surface
charge and other surface modifications. This extensive area of research
has been summarised in recent reviews [1,168] and will only be briefly
covered in this article. Radiolabelling liposomes of different composi-
tions is a convenient way to assess the effect of individual modifications
on their whole-body distribution and has been used since the early days
of liposomal development [35,169]. For example, Richardson et al.
showed greater uptake in rat tumours when using negatively charged
liposomes [35]. The high uptake of liposomes by the RES has been
known since the early days of liposome research. As a consequence,
many strategies were investigated to reduce RES uptake and increase
circulation times, using various radiolabelling methods to investigate
the effect of RES blockade [170], liposome size, charge, dose, and lipid
composition [105,118,171–173], mostly in health animals. The first
study to report an increased uptake of a long-circulating liposomes in
tumours was published by Gabizon and Papahadjopoulos [174].
With the increasing availability of radiometals for biomedical re-
search, it is perhaps surprising that so many studies still rely on 99mTc
and planar scintigraphy. The study by Helbok et al. described in
Section 3.1 took the approach of comparing instead different radionu-
clides for a same lipid formulation [58]. A formulation flexible enough
to accommodate different radionuclides would give the user the flexi-
bility to choose themost appropriate radiometal for the intended appli-
cation. Here the formulation including DTPA was found acceptable
(stable and with high specific activity) for 99mTc, 111In and 68Ga, but
sub-optimal for 177Lu. Beyond the proof of feasibility, however, a
short-lived radionuclide such as 68Ga is not an ideal candidate for imag-
ing formulations with long circulation times, and longer-lived PET ra-
dionuclides should be preferred. Bo et al. used 89Zr to image liposomes
made from cancer cell membranes rather than synthetic lipids, with
good stability of the labelling method over 72 h demonstrated by the
low uptake of 89Zr in the bones [82]. This could be a useful approach
to investigate whether the type of cancer cell fromwhich the liposomes
aremade affects their distribution. Another option for increasedflexibil-
ity is to take advantage of nuclideswith several radioisotopes. For exam-
ple, the formulation by Engudar et al. mentioned previously in
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SPECT imaging and Auger therapy, or 131I for beta therapy [167].
Sou et al. have studied drug delivery to the bonemarrow bymodify-
ing the surface of liposomes with an anionic lipid ester [175,176]. The
spatial resolution of nuclear imaging does not always allow easy differ-
entiation between uptake in the bone and bone marrow in rodents, re-
quiring the use of larger animals (e.g. rabbits) and independent
confirmation of uptake, at least for initial studies. Here, dual fluorescent
labelling of both the lipidmembrane and aqueous compartment proved
the integrity of the liposomes inside the bonemarrow, and transmission
electron microscopy showed the intracellular distribution within bone
marrow macrophages [175]. Such detailed investigations are particu-
larly welcome and show that a further challenge lies in demonstrating
whether the encapsulated cargo can reach targets located outside
endosomal vesicles. Nonetheless, Lee et al. labelled bone-marrow
targeting liposomes with 64Cu andwere able to observe PET signal orig-
inating from the bone marrow in mice femurs [74]. A combination of
small size, negatively charged surface and reduced PEG load resulted
in an increased bone marrow uptake compared to Doxil®-like lipo-
somes. Jestin, Mougin-Degraef and collaborators developed lipid
nanocapsule formulations that could be radiolabelled with multiple ra-
dionuclides (99mTc, 111In, 125I, 131I) [55,56,177]. Although these systems
were intended as vehicles for radionuclide therapy, using for example
90Y or 211At, dual labelling of the membrane lipids and encapsulated
contents is a useful way to assess the integrity of the nanomedicine for-
mulation after delivery. In this case, the stability of the formulation in
blood followed by urinary elimination of 125I showed the disintegration
of the carrier after uptake in the liver and spleen [56]. This aspect is
often overlooked and simply assumed from the appearance of biological
effects of the cargo. An example of this approach was recently given by
Lamichhane et al., who encapsulated an 18F-labelled derivative of
carboplatin into liposomes surface-labelled with 111In by SPECT to di-
rectly observe the in vivo stability of the formulation. Similarly, Medina
et al. radiolabelled an EGFR inhibitorwith 124I and encapsulated it inside
111In-labelled liposomes [109]. Clear differences in the biodistributions
of the radionuclides were noted after 24 h, indicating the release of
the drug from the liposomes. There are nonetheless limitations to this
approach.While covalent radiolabelling of a molecule offers unambigu-
ous determination of its location, as opposed to co-encapsulation of a ra-
dionuclidewhich is then assumed to distribute similarly to the drug, not
all drugs can be radiolabelled this way and it should still be determined
that the therapeutic drug and its radiolabelled derivative have similar
pharmacokinetics. Furthermore, the use of 18Fwill only provide stability
information in the first few hours after administration. It is not an ideal
radionuclide to image a drug with an elimination half-life of approxi-
mately 6 h, particularly if it is encapsulated in a long-circulating carrier.
This approach also requires the liposomes to be prepared extemporane-
ously, after the 18F-labelling step. The use of 124I partly solves this prob-
lem but has its own complications since radioiodine-labelled molecules
are prone to deiodination in vivo,meaning that part of the signalmay no
longer originate from the actual drug but from the released radionu-
clide. This additional complexity may limit the applicability of the
dual-labelling approach to a preclinical setting.
The versatility of liposomes as imaging agents can be increased by
multimodal approaches. Certain drugs, such as doxorubicin, are fluores-
cent and therefore radiolabelling liposomal formulations of thesemole-
cules will result in inherently bi-modal imaging tools. Optical and/or
magnetic resonance imaging (MRI) capabilities can be incorporated as
well. For example, liposomes containing DOTA-conjugated lipids were
labelled with Gd3+ for MRI and 64Cu or 111In for nuclear imaging, as
well as fluorescein- or near-infrared dye-conjugated lipids for optical
imaging [72,178], and could additionally be remote-loaded with 99mTc
and doxorubicin. Each imaging modality showed a good retention of
the formulation for 24 h after intratumoural administration [178]. Nota-
bly, Paoli et al. loaded liposomes containing 18F- or 64Cu-labelled lipids
with fluorescent dyes to study the effect on drug release of variouslipid compositions [66]. This study illustrates the benefit of labelling
the encapsulated cargo: although increased drug release in one formu-
lation could be deduced from the appearance of PET signal in the blad-
der (resulting from lipid metabolism), the increased optical signal was
far greater and showed a much broader distribution of the released
dye. To obtain meaningful results from imaging studies, it is therefore
crucial to specifically (radio)label the constituent of interest, i.e. a lipo-
somal membrane component or the cargo. The light-emitting proper-
ties of certain radionuclides have also been exploited to provide
multimodal imaging: Kim et al. radiolabelled liposomes with 124I
[179], which emits Cerenkov radiation and is thus detectable with lumi-
nescence imaging systems. The depth penetration issue of Cerenkov ra-
diation was apparent from the absence of bladder signal in the optical
scans, although this might be solved by re-positioning the animal for a
second scan, which is easily feasible with little consequences because
of the short acquisition times (a few minutes) required for lumines-
cence imaging. Liposomal degradation was apparent from the signal
emanating from the thyroid after 24 h, both by optical and PET imaging.
Most studies of radiolabelled liposomes provide data on the in vitro
stability of the formulation, but few have investigated in depth the
in vivo release of radiolabelled molecules from liposomes. To establish
an in vitro-in vivo correlation (IVIVC), Hühn et al. encapsulated [18F]
FDG into liposomes, injected them intraperitoneally and then used PET
to measure the uptake of [18F]FDG in the brain [180], where this tracer
naturally accumulates after reaching the circulation. Thus, appearance
of signal in the brain could only come from radiotracer release from
the liposomes. Similar approaches could be envisaged with other radio-
nuclides, using for example the uptake of radioiodine in the thyroid or
89Zr in the bone to determine liposomal stability. The development of
IVIVCs for liposomal formulations would be highly beneficial for their
clinical development, giving much more power to the routinely per-
formed in vitro stability tests, and nuclear imaging can certainly play an
important role in progressing these drugs towards the clinic. A recent
and noteworthy example of in vivo analysis of drug release is provided
by Mukai et al., who combined PET imaging of 64Cu-labelled oligonucle-
otides with LC-MS/MS analysis of tissue samples [181]. Mass spectrome-
try showed that the oligonucleotides were so rapidly degraded in vivo
that they could only be detected intact in the kidneys, the PET signal
therefore representing mostly metabolites and/or unchelated 64Cu. In
contrast, encapsulating the oligonucleotides in liposomes preserved
them from degradation. The comparison of PET and LC-MS/MS data
showed that release of the oligonucleotides from the liposomes and sub-
sequent degradation occurred much faster in the liver than in other tis-
sues. With the liposomal oligonucleotides, the PET signal in the tumour
increased over 48 hwhereas the amount of intact oligonucleotide deter-
mined bymass spectrometry peaked around 24 h. Consequently, the PET
signal in the organ of interest is a measure of the cumulative drug deliv-
ery, but the actual fate of the drug is more accurately measured by other
means. Considering the relatively wide availability of LC-MS/MS and the
possibility of preserving samples for off-site analysis, this is a technique
that we feel should be far more frequently used in conjunction with nu-
clear imaging, certainly at the preclinical development stage.
4.2. Oncology
4.2.1. Diagnosis
Although liposomes were initially studied mostly for their use as
drug carriers [1], the use of radiolabelled liposomes in oncology started
briefly after their invention when Gregoriadis et al. first administered
131I-loaded liposomes in three cancer patients and observed a much
higher uptake in cancerous kidney tissue compared to healthy tissue
[103]. The first imaging studies were performed a few years later by
Richardson et al., using 99mTc, and already hinted at potential differ-
ences between animal tumour models and human tumours, and be-
tween patients [36,38]. Further studies helped to establish the safety
of liposomes in patients and showed that radiolabelled liposomes
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[182–188]. With the gradual shift towards the use of long-circulating,
PEG-coated liposomes, the variability of the EPR effect in humans be-
come even more apparent, as illustrated in the landmark study by Har-
rington et al. [189]. A drawback of using radiolabelled liposomes for
tumour imaging is their slow accumulation in tumours, and many of
these clinical studies found that diagnostic accuracy was improved
when imaging was delayed by 24-48 h after administration
[183,184,190]. From a clinical perspective, this complicates logistics by
requiring the patient to attend at least 2 visits, and radiolabelled lipo-
somes appear not to have been usedmuch further in a purely diagnostic
setting. Considering the established clinical use of [18F]FDG and other
PET radiotracers, with excellent performance in cancer diagnosis and
staging, it seems unlikely that liposomes will be used for tumour detec-
tion. In recent preclinical studies,Wong,Mahakian, Rygh and colleagues
provided useful comparisons of 64Cu-labelled liposomes, 64Cu-labelled
albumin and [18F]FDG, showing that the liposomes were superior to
[18F]FDG in detecting small tumours and revealing heterogeneities
within tumours, especially when imaging after 18-24 h [67–69]. 64Cu-
labelled liposomes could be a useful alternative to [18F]FDG for tumours
located close to organswith constitutively high [18F]FDG uptake such as
the brain, the heart, and the kidneys/bladder. This comes at the expense
of high background signal of radiolabelled liposomes in the abdominal
region and the requirement for delayed imaging, which are clear limita-
tions of the technique and would still favour [18F]FDG as a general ra-
diotracer for tumour detection. An additional consideration is that
using a radionuclide with a longer half-life prolongs the exposure of
the patient andmay result in a higher absorbed radiation dose. Interest-
ingly, 64Cu-labelled albumin proved better than liposomes for imaging
increases in vascular permeability during tumour progression, as up-
take in tumours increased more gradually than that of liposomes [67],
and further suggests that radiolabelled liposomes are probably better
for monitoring liposomal drug delivery than for tumour detection.
Using radiolabelled liposomes in conjunction with small-molecule ra-
diotracers could be a strategy to interrogate both the vascular perme-
ability and metabolic status of tumours. The use of radiolabelled
liposomes for the prediction of treatment response and patient stratifi-
cation, where tumour heterogeneity is particularly important, is
discussed further in this review (Section 4.6).
A common issue to both radiolabelled liposomes and [18F]FDG is that
they can fail to differentiate tumours from sterile inflammation or infec-
tious foci. A few recent articles have explored the possibility of using
radiolabelled liposomes containing diagnostic agentswith a higher spec-
ificity for tumours. One such approach is to use radiolabelled antisense
oligonucleotides that recognise mRNA sequences coding for proteins in-
volved in tumourigenic processes [191]. The high specificity of the
probes offers the potential to achieve high target-to-background ratios,
but the bioavailability of nucleic acids is poor and carrier systems, includ-
ing liposomes, are generally required for effective delivery [192]. Fu et al.
incorporated 99mTc-labelled antisense oligonucleotides directed against
the MDM2 oncogene into liposomes (Lipofectamine®) and observed a
3-fold increase in tumour uptake compared to amismatched oligonucle-
otide [193]. Some accumulation of themismatched probe in the tumours
can be seen in the SPECT images, likely due to EPR-mediated uptake.
Using the same liposomal carrier, Liu et al. imaged an antisense nucleo-
tide directed at telomerase reverse transcriptase, based on the fact that
many tumour cells maintain their proliferative ability by sustaining telo-
merase [194]. In this study, although the tumour uptake of the antisense
probe was far higher than the sense probe, the imaging study revealed
no difference between the liposome-encapsulated and non-
encapsulated formulations, in direct contradiction of the observed
in vitro effectiveness of this strategy. In the absence of full biodistribution
data, it is not clear whether the liposomal formulation led to differences
in biodistribution of the oligonucleotide probe. Nonetheless, these two
studies illustrate the benefit of imaging the encapsulateddrug,whenever
possible, rather than the carrier. In the first study, it is not determinedwhether liposomal encapsulation provides any benefit, and a non-
liposomal control would have been warranted. In the second study,
radiolabelling the liposomes on their surface or remote-loading a radio-
nuclide that does not bind to the cargowould probably not have revealed
the specific accumulation of the antisense oligonucleotide. Another ap-
proach is to coat liposomes with tumour-targeting peptides, directed
for example against integrin αVβ3, a protein overexpressed in many tu-
mours [195]. Kang et al. radiolabelled αVβ3-targeting liposomes with
64Cu to monitor tumour angiogenesis [73]. Despite the images showing
a higher and faster uptake of 64Cuwith the targeted liposomes compared
to non-targeted liposomes, the intense accumulation in the liver did not
compare favourably to an existing small-molecule, 18F-based radiotracer
targeting the same protein.
4.2.2. Drug delivery
Despite liposomes being extensively researched as drug carriers,
very few studies of radiolabelled liposomes until the early 2000s in-
cluded formulations containing an active pharmaceutical ingredient
[123,196,197]. While it may seem easier to use ‘empty’ liposomes, i.e.
not containing any cargo, co-encapsulating a drug and a radiotracer or
encapsulating a radiolabelled drug allow direct correlation of uptake
measurementswith therapeutic efficacy and therefore providemore in-
formation. Two clinical studies by Koukourakis et al. illustrate this ap-
proach, where it was shown in patients with non-small-cell lung
cancer that tumour uptake of 99mTc-labelled liposomal doxorubicin
(Doxil®) correlatedwith tumour vascularisation and appeared to corre-
late with tumour regression, although further data would have been re-
quired to prove the latter [198,199]. Repeated administration of the
radiolabelled liposomeswas performed and scintigraphy demonstrated
high uptake in tumours both before and after radiotherapy [198], sug-
gesting in hindsight that therewas no significant involvement of the ac-
celerated blood clearance (ABC) effect (see Section 4.6).
A major benefit of using nuclear imaging is the ability to quantify
drug uptake and monitor disease status in organs not readily accessible
by other means. For example, a number of small-molecule PET radio-
tracers are clinically available for brain tumour imaging, such as [11C]
choline, [18F]FDG, [18F]FLT or [18F]FET, but liposomal formulations
could potentially be used both for diagnosis/monitoring and drug deliv-
ery. Increased transport across the blood-brain barrier, a major chal-
lenge in drug development, was demonstrated with 99mTc-labelled
liposomes coated with transferrin [200,201]. 18F-labelled liposomes
proved superior to [18F]FDG in a rat model of glioma, being capable of
detecting very small tumours and showing lower background signal in
the brain [92], although for imaging purposes the added value of an
angiogenesis-targeting peptide compared to non-targeted PEGylated li-
posomes was less evident. In another study, incorporating an
18F-labelled derivative of dasatinib (a platelet-derived growth factor
receptor inhibitor) into liposomes provided no benefit over the non-
encapsulated drug, although it is worth noting these were non-
PEGylated liposomes and can thus be expected to rapidly accumulate
in the RES, and a PEG-based micellar formulation of the same radio-
tracer increased the amount of tracer reaching brain tumours [110].
Onemight speculate that higher accumulation in the brain could poten-
tially be achievedwith longer-circulating liposomes, inwhich case a dif-
ferent radionuclide would certainly be required for useful imaging.
Two recent studies by Patel et al. investigated drug delivery to the
uterus for the treatment of endometriosis [202,203]. Raloxifene and
leuprolide were directly radiolabelled with 99mTc before encapsulation
in liposomes for intravaginal administration. Both drugs have poor uter-
ine bioavailability and significant side effectswhen administered paren-
terally. Scintigraphic imaging revealed much longer retention of the
liposomal drugs in the uterus compared to the non-encapsulated
drugs, and slow release was visible for leuprolide from the delayed ac-
cumulation in the kidneys. Although therapeutic efficacy was not
assessed in these studies, the absence of signal from other organs sug-
gests a low risk of side effects.
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peritoneum by using the avidin-biotin system has been investigated
using nuclear imaging [204–207]. The underlying concept is that the ad-
ministration of avidin can induce the aggregation of biotin-conjugated
liposomes. Another approach to enable the prolonged release of lipo-
somes froma reservoir is to embed them in a hydrogel, which can be de-
livered locally. Alinaghi et al. added 99mTc-labelled liposomes to a
chitosan-glycerophosphate hydrogel which was then administered in-
traperitoneally [208]. The hydrogel formulation significantly increased
the amount of 99mTc in the blood and peritoneal cavity and reduced up-
take in the liver. Beyond the advantages of lower systemic exposure and
higher local concentration conferred by the intraperitoneal or subcuta-
neous delivery modes, radiolabelling allowed both longitudinal studies
and uptake measurements in organs not easily accessible by necropsy.
The trafficking of liposomes to tumours can be increased by local hy-
perthermia, which increases vascular permeability. Nuclear imaging has
been used to demonstrate this with 99mTc-labelled liposomes after
heating with a catheter [209], microwave irradiation [210] or radiofre-
quency ablation [211]. Scintigraphic and SPECT measurements of
99mTc accumulation in the tumours correlatedwell withHPLCmeasure-
ments of intratumoural doxorubicin, although the actual release of the
drug from the liposomes was not studied. Similarly, Oerlemans et al.
used MR-guided focused ultrasound to release 99mTc from liposomes
[212], with confirmation of release from the liposomes provided by
co-encapsulating fluorescein, whose fluorescence exhibits self-
quenching at high intraliposomal concentrations and increases due to
dilution upon release. Encapsulating ammonium bicarbonate into lipo-
somes provided a thermally sensitive yet more stable formulation
than the lysolipid-based ThermoDox® [213]. Here, the lower stability
of ThermoDox® was observed by SPECT with an increased kidney up-
take of 99mTc at early time points, which resulted in lower tumour up-
take and therapeutic efficacy.
Perche et al. prepared electrostatic complexes of radiolabelled
nucleic acids and liposomes, called lipoplexes, to develop a dendritic
cell vaccine [214]. The lipoplexesweremannosylated to increase uptake
by dendritic cells, although this point was proven by ex vivo fluores-
cence measurements. Since the distribution patterns were similar be-
tween mannosylated and non-mannosylated lipoplexes, the main
lesson from the radiolabelling was the absence of accumulation of the
nucleic acids in the lungs, which can occur after aggregation of the
lipoplexes.
Bisphosphonates are small molecules with high affinity for bone
minerals and are used to combat osteolytic diseases due to their anti-
osteoclastic action. Liposomal encapsulation of bisphosphonates has
been explored as a way of exploiting their anti-cancer properties in
other tissues. Hodgins et al. radiolabelled liposomal alendronate with
111In – using DSPE-DTPA – in amousemodel of melanoma, in combina-
tion with γδ-T cell therapy [215,216]. It is worth noting that the chelat-
ing properties of bisphosphonates enable the direct radiolabelling of
these compounds [143,145] and it might be preferable to use this ap-
proach to image the drug rather than the liposomal carrier. In vitro re-
sults showing improved efficacy of integrin αvβ6-targeting liposomes
compared to non-targeted liposomes were not replicated in vivo,
where imaging showed no difference in tumour uptake or therapeutic
efficacy. The combination with γδ-T cells demonstrated strong anti-
tumoural activity, suggesting the additional complexity of targeting li-
posomes may not be required for this type of cell therapy.
On the other hand, 111In-labelled liposomes decorated with an
internalising scFv showed a fourfold increase in tumour uptake com-
pared to untargeted liposomes and very high tumour-to-blood and
tumour-to-muscle ratios (Fig. 8A) [59]. Thiswasmirrored by a lower up-
take in the liver and spleen. The slightly higher kidney uptake with the
targeted formulation may suggest a competing effect between the scFv
and 111In-DTPA groups on the liposomal surface leading to the release
of 111In, or some liposomal degradation upon internalisation. It would
be valuable to determine whether this increased uptake can deliverimprovements in therapeutic efficacy. Interestingly, this study deter-
mined the optimal amount of targeting moiety to promote
internalisation. As a counterpoint, Christensen et al. recently showed
that 64Cu-labelled folate-targeting liposomes had lower tumour uptake
than non-targeting liposomes in vivo despite numerous reports of in-
creased uptake in vitro, the authors suggesting that the targeted receptor
was not accessible to the liposomes and that the EPR effect was predom-
inant [217]. Aside from the differences in tumour models, which may
have varying degrees of vascularisation and EPR effect [218], these dis-
crepancies could also be due to the specific targetingmoieties, the extent
towhich they promote internalisation and their density on the liposomal
surface. These studies using targeted liposomes highlight the value of nu-
clear imaging: the question of whether the targeting of these nanoparti-
cles is effective can be rapidly answered, usuallywithin 24 h. The need to
wait for a biological response (e.g. changes in tumour size), which typi-
cally takes several days and may require multiple administrations, is
also removed. They also highlight the importance of including non-
targeting formulations as controls for in vivo experiments, since in vitro
results cannot be assumed to be predictive.
4.2.3. Radionuclide therapy
Liposomes can be labelled with radionuclides suitable for radionu-
clide therapy, such as the alpha-emitters 166Ho, 225Ac and 213Bi
[63,102,135,136,219], beta-emitters 90Y, 131I, 159Gd, 177Lu
[62,101,121,131,220] or 186Re/188Re [154,157,159,160,221–225], and
Auger electron-emitters 111In or 125I [177,226–228]. The advantages
and disadvantages of using each type of particle in anticancer radiother-
apy are beyond the scope of this article but have been reviewed recently
elsewhere [229,230]. There are nonetheless practical implications for li-
posomal formulations. The very short range of Auger electrons (a few
nm)means these radionuclides need to be delivered as close as possible
to the cell nucleus to cause damage. Alpha- and beta-emitters have
much larger energy deposition volumes and therefore liposomal escape
from endosomal vesicles and release of the radionuclide from the lipo-
some are not required for therapeutic efficacy, with the downside of
an increased radiation burden to neighbouring healthy cells. Several of
the above radionuclides also emit gamma rays, enabling simultaneous
imaging and treatment (see Table 1). Fondell et al. illustrated this con-
cept with a liposomal formulation incorporating a 125I-labelled dauno-
rubicin analogue, in which the damage to tumour cells was driven by
the emissions from 125I rather than the DNA-intercalating properties
of the drug [226]. Another example is given in the studies by Lin,
Chow and colleagues using formulations combining 111In and the che-
motherapeutic drug vinorelbin [227,228]. This work highlights the im-
portance of choosing the appropriate models to study, as the
therapeutic effect of liposomal vinorelbin was so pronounced that it
was difficult to evaluate the added value of 111In as a radiotherapeutic
agent beyond its use for imaging. In another study, Zavaleta et al. used
the biotinylated liposome formulation for intraperitoneal deliverymen-
tioned above [206] and substituted 99mTc for 186Re, providing a
radiotherapeutic system that also allowed imaging over 5 days [223].
This flexible labelling approach could be applied to personalized medi-
cine by using the 99mTc-labelled formulation to explore the distribution
of the nanomedicine and following upwith the 186Re-labelled version if
the distribution is deemed favourable, as exemplified in a rat model of
glioblastoma [222]. A similar strategy could be pursued with the
64Cu/177Lu pair of radionuclides described by Petersen et al. [220].
Here, PET imaging of 64Cuwas proposed as a preliminary step before ad-
ministration of radiotherapeutic 177Lu. Considering that the liposomal
formulation led to high accumulation in the liver and spleen, amore de-
tailed study would be welcome to assess whether sufficient amounts of
177Lu can be delivered to the tumour while minimising hepato-splenic
toxicity. Liposomes loaded with 188Re were studied in several tumour
models and appearedwell-tolerated, with accumulation in tumours ob-
servable by SPECT, but could not eradicate established tumours at toler-
ated doses [157–159], although the co-encapsulation of doxorubicin
Fig. 8. Preclinical and clinical examples where nuclear imaging has been used to answer specific liposomal therapy questions. (A) Introduction of a single chain antibody (scFv) tumour-
targeting group into liposomes (immunoliposomes– ILs) improves tumour uptake. (Top) SPECT/CT images of 111In-ILs 24 h after injection showing uptake of in both epithelioid (M28) and
sarcomatoid (VAMT-1) mesothelioma tumours. (Bottom) ILs show higher tumour uptake compared to non-targeted liposomes (CLs). Adapted with permission from Iyer et al. [59],
Copyright 2011 Elsevier. (B) Glucocorticoid-loaded PEGylated liposomes radiolabelled with 111In demonstrate high-EPR mediated uptake over time in inflamed joints in a model of
rheumatoid arthritis. Adapted with permission from Metselaar et al. [129], Copyright 2003 John Wiley and Sons. (C) PEGylated liposomes radiolabelled with 89Zr allow non-invasive
quantification of therapeutic liposome (e.g. Doxil®) tumour uptake using PET (top) and allow therapeutic efficacy prediction based on PET signal concentration at the tumour
(bottom). Adapted from Pérez-Medina et al. [79] under CC-BY license [275]. (D) (Top) Maximum intensity projection PET images of a patient with HER2-positive breast cancer
injected with 64Cu-MM-302. As expected from long circulating liposomes at 0.6 h post injection most activity is in circulation, and only from day 2 is significant uptake in RES organs
and tumour lesions evident. (Bottom) A correlation between 64Cu-MM-302 tumour uptake levels (high or low) and patient progression-free survival (PFS) is seen, although not
statistically significant due to low numbers. Adapted by permission from the American Association for Cancer Research: Lee et al. [163].
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and increase the therapeutic efficacy, local delivery to the tumour has
been explored as an alternative to the intravenous route. Studies using
186Re-loaded liposomes demonstrated therapeutic efficacy in a tumour
resectionmodel, particularly for cationic liposomes compared to neutral
liposomes due to increased retention at the site of administration
[221,232]. Imaging demonstrated much lower uptake in the liver thanwould be expected after systemic administration. Here, radionuclide
therapy is envisaged as an adjunct to surgical resection, to kill residual
tumour cells. Together, this body of research suggests that radionuclide
therapy delivered by liposomes is probably best used in combination
with other treatment modalities rather than as an alternative to
chemo- or radiotherapy. Finally, formulations combining paramagnetic
metals and therapeutic radionuclides have potential for multimodal
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studies do not appear to have progressed beyond the in vitro stage
[63,101].
4.3. Infection, inflammation
Nuclear imaging of infections was historically performed with 67Ga-
citrate, 111In-immunoglobulin G or white blood cells radiolabelled with
111In-oxine or 99mTc-HMPAO. Due to the increased blood flow and vas-
cular permeability, and in some cases increased phagocytic activity, li-
posomes also accumulate in inflamed tissue areas. This property has
been exploited to deliver anti-inflammatory and antibiotic compounds
[233–237]. The most used drug in this category is AmBisome® [238], a
liposomal formulation of amphotericin B, although in this case the
main benefit of the liposomal formulation is simply a reduction in tox-
icity [239]. Radiolabelled liposomes can also be used to identify sites
of infection and inflammation [240–242], particularly as an easier alter-
native to the comparatively complex use of radiolabelled white blood
cells. Liposomes also proved superior to 67Ga citrate in neutropenic rat
models of bacterial and fungal infection [243], where the number of cir-
culating leukocytes would be too low for radiolabelling, although now-
adays [18F]FDG PET seems more indicated in such cases [244].
Andreopoulos et al. attempted to use 99mTc-labelled liposomes as vehi-
cles to radiolabel white blood cells in whole blood [245], to solve the
problem of 99mTc efflux from leukocytes after HMPAO-mediated label-
ling and to avoid the lengthy leukocyte isolation process. However,
the radiolabelling efficiency was very low and the activity concentrated
mainly in mononuclear cells, which are not the main responders to in-
fections. One of the earliest studies of radiolabelled liposomes to detect
infectious abscesses was that performed by Morgan et al., where nega-
tively charged liposomes rapidly accumulated in abscesses caused by
Staphylococcus aureus [246]. Orozco et al. observed amuch higher accu-
mulation of radiolabelled liposomes in the lungs of tuberculous mice
compared to normalmice [247],whichmight have explained the higher
efficacy of their liposomal formulation of rifampicin and isoniazid. The
study by Bakker-Woudenberg et al. in a Klebsiella pneumoniae model
is particularly interesting in that it showed a strong correlation between
liposomal uptake in the lungs and the severity of infection, assessed
both by the mass of the lungs and the number of bacteria present
[248]. For example, Sikkink et al. have used liposomes labelled on
their surfacewith 99mTc to detect abdominal abscesses in a rat peritoni-
tis model [48], showing good correlation between focal uptake of lipo-
somes and the presence of intra-abdominal adhesion and potential for
treatment monitoring. Based on the local acidification that occurs in in-
flamed tissues, Carmo et al. have used pH-sensitive liposomes labelled
with 99mTc to detect sterile inflammation foci [249], claiming faster
and higher uptake than for non-pH-sensitive formulations [242,250].
This would enable faster and more robust detection of inflammation,
although the study unfortunately did not include a direct comparison
between formulations and the disease model was different (sterile
inflammation vs. S. aureus osteomyelitis). Distinction between bone
infection and sterile inflammation in later studies with ceftizoxime-
encapsulating pH-sensitive liposomes was less evident, despite im-
proved uptake in the bones with alendronate-coated liposomes
[251,252]. More generally, this is a shortcoming of many studies using
radiolabelled liposomes. It is not sufficient to claim that a formulation
can detect foci of infection or inflammation. To help clinical adoption,
studies should include additional experimental comparisons and make
the case that radiolabelled liposomes are equivalent or better than cur-
rently used tracers, as exemplified in preclinical studies comparing lipo-
somes with radiolabelled leukocytes or immunoglobulin G (IgG)
[253,254]. A direct, within-subject comparison of 99mTc-labelled lipo-
somes and 111In-IgGwas performed in 34 patientswith suspected infec-
tion or inflammation. The liposomes showed marginally higher
sensitivity, similar specificity and generally improved image quality
over radiolabelled IgG [255]. The only other clinical trial of radiolabelledliposomes for infection was performed by Weers et al. with liposomal
amikacin for inhalation (LAI) and showed prolonged retention of activ-
ity in the lungs, although it was only assessed in healthy volunteers
[256]. LAI is still under clinical evaluation, and a recent trial reported in-
conclusive results in patient with pulmonary non-tuberculous myco-
bacterial disease [257]. Incorporating imaging in such studies would
provide a better picture of drug distribution than blood sampling and
potentially elucidate whether treatment failure is caused by inadequate
drug distribution or bacterial resistance.
The first clinical reports of accumulation of radiolabelled liposomes
in patients with rheumatoid arthritis were probably those by Morgan,
Williams, O’Sullivan and colleagues [258–261] in the late 1980s, already
suggesting the use of such formulations to monitor phagocytic activity
in the synovial tissue as better markers of disease status than the ana-
tomical changes observed by X-ray imaging. Furthermore, Zalutsky
et al. suggested using 111In-labelled liposomes for radiation
synovectomy [262]. In veterinary medicine, Underwood et al. have
shown that liposomes could detect laminitis in horses and highlighted
potential systemic inflammation in this debilitating disease [263,264].
Türker et al. administered 99mTc-labelled liposomes intra-articularly to
study their retention [265]. Although the radiolabellingwas not specific
to any constituent of the liposomes, scintigraphy showed good reten-
tion of the radiotracer in the inflamed joints, andurinary excretion of re-
leased 99mTc but not hepatosplenic uptake. This approach could be
useful for anti-inflammatory drugs with hepatosplenic toxicity or rap-
idly degraded in the liver. Corvo et al. showed that subcutaneous admin-
istration of small-sized (b 150 nm) liposomes loaded with superoxide
dismutasewas equally effective as the intravenous route in reducing in-
flammation [100,130]. In another therapeutic study, Metselaar et al. ob-
served that liposome encapsulation of prednisolone significantly
increased the therapeutic activity compared to the non-liposomal
drug, and imaging showed that this was due to the increased circulation
time and accumulation of the drugs in the joints (Fig. 8B) [129]. This
product is now in phase III clinical trials for rheumatoid arthritis treat-
ment (NCT02534896). Liposomal prednisolone was recently evaluated
in a clinical trial for atherosclerosis treatment, and the samegroup of au-
thors commented that the apparent absence of therapeutic response
may have been due to insufficient drug accumulation and that this un-
certainty could have been solved by using non-invasive imaging such
as radiolabelled liposomes [266].
Apart from arthritis, radiolabelled liposomes have also been used in
models of abdominal inflammation (colitis, inflammatory bowel dis-
ease, Crohn’s disease) [49,267,268] and brain inflammation [269]. Nota-
bly, in a study by Awasthi et al., 99mTc-labelled liposomes performed
better than 111In-labelled leukocytes [268].
Saari et al. conducted as series of clinical studies in healthy volun-
teers and asthmatic patients using 99mTc-labelled liposomes loaded
with beclomethasone, a corticosteroid widely used as a non-liposomal
aerosol in asthma management [270–273]. Scintigraphy showed that
the lung deposition of the liposomal formulation was not affected by
concomitant treatment with a long-acting β2-agonist. Although the de-
velopment of this liposomal formulation does not appear to have con-
tinued, these studies show that using nuclear imaging is an interesting
option to evaluate interactions betweendrugs in combination therapies.
More recently, Behr et al. imaged liposomal cyclosporine A in lung
transplant recipients, showing good deposition in the lungs [274].
A common feature of the studiesmentioned here is that the sensitiv-
ity of nuclear imaging for the detection of infectious and inflammatory
foci is somewhat offset by the difficulty in distinguishing these two phe-
nomena. There are therefore opportunities to develop targeting strate-
gies to improve diagnostic accuracy and drug delivery.
4.4. Cardiovascular
Recently, Ogawa et al. have used 111In-labelled liposomes to image
atherosclerotic plaque, exploiting the presence of infiltrated
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with phosphatidylserine to mimic apoptotic cells and trigger phagocy-
tosis by themacrophages. Despite encouraging ex vivo autoradiography
results, whole-body images were more difficult to interpret due to the
proximity with the liver. It is possible a different radionuclide would
provide better results; nonetheless this is an interesting application of
radiolabelled liposomes as diagnostic tools.
Blood pool imaging by scintigraphy is typically done with 99mTc-
radiolabelled autologous erythrocytes or human serum albumin
(HSA). A few studies have explored the use of radiolabelled liposomes
as a replacement for these products, to simplify the procedure and re-
duce the risk of contamination from handling blood. Despite results
showing good stability of the 99mTc label, sufficient circulation times
and biodistributions that were similar to radiolabelled erythrocytes
and better than 99mTc-HSA in healthy animals [44,277,278], PEGylated
liposomes do not appear to have been further studied for diagnostic
purposes in this context. On the other hand, liposome-encapsulated
haemoglobin as a substitute for red blood cell transfusions have seen
continued interest, and radiolabelling with 99mTc has contributed to es-
tablishing their therapeutic potential [279–281]. A PET alternative was
developed by Urakami et al. using an 18F-based probe that can be incor-
porated into preformed liposomes [91].
Early studies of liposomes in myocardial infarction used dual-
radionuclide radiolabelled liposomes with 99mTc to follow the lipid
components and entrapped 125I-HSA or 125I-polyvinylpyrrolidone in
the aqueous compartment [104], or 3H-cholesterol and 99mTc-DTPA re-
spectively [282]. This strategy helped assess the integrity of the lipo-
somes in the circulation. Although no imaging was performed at the
time, dual-radionuclide SPECT is feasible with the current generation
of scanners and should be exploited further. These earlier studies were
inconclusive as to the usefulness of liposomes for drug delivery vehicles
in myocardial infarction. Liposomes loaded with 99mTc-radiolabelled
streptokinase have been used to image thrombi, showing a modest in-
crease in streptokinase accumulation at the target site [283]. The im-
provement was however too modest to envisage using these
liposomes to detect thrombi. Later developments with
immunoliposomes [284,285] or other surface modifications to target
markers of vascular damage and platelet activation such as lectin-like
oxidized low-density lipoprotein receptor-1 (LOX-1), chondroitin sul-
fate proteoglycans or integrin GPIIb/IIIa, have increased the therapeutic
potential of liposomes in cardiovascular diseases [286]. For example,
Zhang et al. have developed liposomes incorporating 18F-
fluorodipalmitin in the lipid membrane and coated with an arginine-
rich peptide [86]. Dynamic PET imaging demonstrated very rapid accu-
mulation in the heart vasculature andmyocardium, which was reduced
in mouse models of infarction and reperfusion injury [87]. Such formu-
lations could thus be used both to deliver drugs to themyocardium and
diagnosemyocardial ischaemia. In this case the rapid kinetics could jus-
tify the use of a short-lived radionuclide, but the need to formulate the
liposomes after radiosynthesis of the 18F-labelled lipid is a significant
disadvantage. Remote loading or surface chelation of a radiometal
such as 68Ga immediately prior to administration would probably
have better prospects for clinical translation.
In this light, the approach recently demonstrated by Hood et al.
could prove useful for vascular imaging and drug delivery [61]. Lipo-
somes with DTPA-functionalised lipids were radiolabelled with 111In
prior to administration. Conjugating the liposomes to monoclonal anti-
bodies or single-chain variable fragments (scFvs) targeting the vascular
integrins PECAM-1 and ICAM-1 showed higher accumulation in the
lungs than non-targeted liposomes. Furthermore, the scFv-conjugated
liposomes had increased specific targeting, presumably because the ab-
sence of the Fc region reduced the potential for uptake by the RES.
Ishii, Fukuta and colleagues used radiolabelled liposomes to detect
cerebral ischemia-reperfusion injury. Liposomes containing a 125I-
labelled erythropoietin analogue showed increased uptake in the ische-
mic hemisphere when injected immediately after reperfusion,accompanied by reduction in brain swelling and improvedmotor scores
compared to the non-liposomal drug [108]. However, using a similar
liposome radiolabelled with 18F but containing no drug, while the in-
crease in 18F uptakewas higher in the ischemic side of the brain, the sig-
nal intensity was similar on both sides, making the use of such
liposomes difficult for diagnosis [93]. A potential reason for this was
that the increased uptake, presumably due to increased vascular perme-
ability, was offset by the reduction in blood flow. The reasons for the
discrepancy between the 125I- and 18F-labelled formulations are un-
clear, although we speculate that retention of the EPO analogue and
its carrier maybe be different after release. This question could be an-
swered by radiolabelling both the encapsulated drug and the carrier.
4.5. Other
Liposomes have been used for topical formulations in ophthalmol-
ogy, as the layered structure of the mammalian eye presents many bar-
riers to the delivery of therapeutic concentrations of drugs [287].
Cationic liposomes radiolabelled with 111In [288] or 99mTc [289–291]
had longer pre-corneal residence times after ocular instillation, leading
to increased corneal penetration and therapeutic benefits in a rabbit
model of cataract. For this application the relatively short half-life of
99mTc was an advantage, as the clearance of the liposomes from the
eye occurred within a shorter time frame. From a clinical perspective,
however, it would seem safer and probably less expensive to use ocular
fluorophotometers [292] and fluorescently labelled liposomes to mea-
sure corneal drug delivery, rather than the comparatively burdensome
use of radionuclides.
In dermatology, liposomes and other nanoparticulate formulations
have been explored as vehicles, usually to increase transdermal drug
delivery, with mixed results [293]. On the other hand, one study used
99mTc-labelled liposomes to show an increased skin retention and re-
duced liver uptake of octyl methoxycinnamate, a photoprotective com-
pound widely used in sunscreens [294].
Liposomes have been investigated as drug delivery vehicles in
Alzheimer’s disease, encapsulating an 18F-labelled curcumin analogue
or using an 18F-labelled lipid to track the liposomes and coating the sur-
face with a peptide targeting low-density lipoprotein (LDL) receptors to
increase uptake in the brain [295]. By the authors’ own admission, the
half-life of 18F was too short to match the pharmacokinetics of the lipo-
somes and overall uptake in the brain was low. A superior brain-to-
blood ratio was claimed for the LDL-targeting formulations, but this
measure can be misleading as it is likely that the very low circulating
levels of the liposomes – as a consequence of higher liver and lung up-
take values – influence these results. Expressed as SUV, uptake in the
brain was in fact no higher than with the non-targeted formulations.
Moreover, spatial patterns of 18F uptake in the brain did not coincide
with the distribution of amyloid plaque. Finally, curcumin and its deriv-
atives have long been known as problematic compounds (PAINS, for
pan-assay interference compounds) in drug development, interfering
in many assays and one should therefore exercise caution before envis-
aging to use curcumin analogues for targeting purposes.
Recently, T.M. e Silva et al. reported higher accumulation in the liver
of galactosylated liposomes, as a potential drug delivery vehicle for he-
patic diseases [53]. Since liposomes generally have high uptake in the
liver, it remains to be seen whether this accumulation occurs preferen-
tially in hepatocytes rather than Kupffer cells and whether this ap-
proach can have therapeutic benefits. Amin et al. attempted to use
nasally delivered liposomes for tetanus vaccination [296]. Scintigraphy
imaging showed good deposition and retention of the formulation in
the nasal mucosa. This strong interaction with the mucosa may have
prevented the liposomes from reaching the lymph nodes, explaining
the failure of the formulation to elicit a systemic immune response.
The slower clearance of liposomes compared to small-molecule
drugs has been exploited to demonstrate improvements in scanner
technology.Wirwarr et al. used 111In-labelled liposomes to demonstrate
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SPECT system [297], and Prior et al. used similar liposomes to improve
scatter correction in dual-radionuclide SPECT [298]. Combined with
sub-millimetre spatial resolution, such technological advances have
played a great part in keeping SPECT radionuclides relevant in preclini-
cal research despite the gradual shift towards the use of PET in the clinic.
In nearly all the studies cited, the sole role of the chelator is to enable
the incorporation of a radiometal in a liposome formulation. One study
took the opposite approach, using 99mTc to assess the delivery of DTPA
for use in chelation therapy [299]. Here, the tropism of liposomes for
the liver is beneficial since this is the site of accumulation of toxic
heavy metals such as thorium and plutonium.
4.6. Personalised medicine
An area of medicine where radiolabelled liposomes – and
radiolabelled compounds more generally – hold particular promise, is
personalised medicine [8], a concept first proposed by Harrington
et al. after observing heterogeneous uptake of liposomes in patients
[189]. The ability to predict which patients have a higher probability
to respond or not to a given treatment would help tailor the treatments
and thus avoid unnecessary treatment to patients who would only ex-
perience the adverse effects of drugs. This is particularly relevant for li-
posomal drugs in oncology. Indeed, the EPR effect, which is the main
driver of their accumulation in tumour sites, is known to be highly var-
iable not only between patients, but even between tumours within the
same patient [5,300]. Furthermore, many current therapeutic ap-
proaches in oncology target the tumour vasculature and can therefore
affect tumour uptake of liposomes. Consequently, radiolabelled lipo-
somes could be used to adjust treatments in real time. Previous re-
viewers of the field commented on potential applications in
personalised medicine [301]. It is exciting to see that in recent years,
studies have emerged specifically examining the use of radiolabelled li-
posomes in personalised medicine, which we address below.
Using four different tumour models, Ito et al. observed different re-
sponses to liposomal doxorubicin (Doxil®) that correlated with the up-
take of drug in the tumours and the degree of tumour vascularisation,
both measured by ex vivo histology [302]. They then showed that the
uptake of 111In-labelled liposomes of similar composition correlated
with therapeutic efficacy, proving that non-invasive imaging could be
used to predict treatment outcome. Similarly, Pérez-Medina et al. used
a PEGylated liposomal formulation radiolabelledwith 89Zr as a compan-
ion PET imaging agent for Doxil® [79,80]. Therewas a strong correlation
between the tumour uptake of 89Zr measured by PET and the amount of
doxorubicin in the tumours, which further translated into a good corre-
lationwith tumour growth delay (Fig. 8C) [79]. Despite DFO often being
described as a sub-optimal chelator for 89Zr, the images at 24 h do not
seem to show significant uptake in the bone, proving the stability of
the formulation. It is especially noteworthy that this study demon-
strated good correlation between the uptake of 89Zr and that of other,
non-liposomal nanoparticulate formulations such as a nanoemulsion
and a PLGA block copolymer nanoparticle, demonstrating that a single
formulation could potentially be used as a companion diagnostic for
any drug whose uptake is primarily EPR-mediated. This would consid-
erably simplify translation by removing the need to gain regulatory ap-
proval for radiolabelled versions of each liposomal or nanoparticulate
drug. In a radionuclide therapy model, Hrycushko et al. found that tak-
ing into account intratumoural heterogeneity for absorbed-dose calcu-
lations after local delivery of 186Re-labelled liposomes provided better
correlation with tumour shrinkage than using the average tumour
absorbed dose [303]. While such precise intratumoural distribution
analysis is non-trivial, it is expected that future technological improve-
ments will simplify this type of analysis, and will allow to correlate for
example the spatial distribution of a radiolabelled drug with the thera-
peutic outcomewithbetter accuracy than simply using the total amountof drug delivered to the tumour. This is more likely to be achievable
with PET imaging because of the increased sensitivity and spatial reso-
lution. It should be kept inmind that it is difficult to replicate the hetero-
geneity of human tumours with xenograft models, and the use of
spontaneous tumour models should be considered when developing
personalised medicine approaches [301].
In the clinic, Arrieta et al. administered 99mTc-labelled liposomal
doxorubicin in combinationwith cisplatin to patients with unresectable
malignant pleural mesothelioma [304,305]. By dividing patients into
groups showing ‘low’ or ‘high’ tumour uptake of 99mTc as measured by
SPECT, it was demonstrated that patients with high uptake had signifi-
cantly higher response rates than those with low uptake. Although the
study only included 35 patients, the results suggest that the patients
with low uptake could be spared this particular treatment and be
switched to alternative treatments. Recently, a body of preclinical and
clinical work with 64Cu-labelled liposomes has been described by Lee
et al. [161,163,164]. Anti-HER2-targeted liposomes loadedwith doxoru-
bicin were radiolabelled using 4-DEAP-ATSC as radiolabelling agent
(see Section 3.2.4), a method that has the advantage of not requiring
prior encapsulation of a copper chelator and is therefore applicable to
any liposomal formulation. Imaging data led to classifying patients as
having ‘low’ or ‘high’ uptake in the tumour lesion with the lowest up-
take, and there appeared to be correlation between progression-free
survival and 64Cu uptake (Fig. 8D) [163]. Despite the good stability of
the 64Cu label inside the liposomes in vitro, better contrast on the PET
images at later time points might have been obtained with the choice
of a longer-lived PET radionuclide. Nonetheless, the results warrant fur-
ther investigations to drawfirm conclusions as to the predictive value of
liposomal 64Cu uptake in tumours. It was then demonstrated in several
preclinical models that the uptake of a 64Cu-labelled liposomal reporter
correlated with the therapeutic efficacy of 3 different liposomal drugs,
but not with that of non-liposomal doxorubicin [164], and enabled the
monitoring of the effects of an anti-VEGF drug [162]. It was recently
shown by Hansen et al. that radiation therapy could affect, positively
or negatively depending on the model, liposomal uptake in tumours
[141], leading the authors to suggest the use of radiolabelled liposomes
to determinewhich patients would be more likely to benefit from com-
bination treatment with liposomal anticancer drugs.
As mentioned previously in Section 4.2.1, predicting the efficacy of
liposomal drugs is probably more accurately done with radiolabelled
liposomes than with [18F]FDG, because the accumulation of this small-
molecule radiotracer in tumours is dependent on metabolic activity
rather than on the EPR effect. There is therefore much potential in
using radiolabelled liposomes to predict treatment outcome. However,
it has long been known that the immune system can recognise PEG
chains on liposomes and other nanosized formulations and raise re-
sponses that lead to rapid clearance of the carrier upon repeated admin-
istration [306]. This phenomenon, known as the accelerated blood
clearance (ABC) effect, is mediated in part by anti-PEG immunoglobulin
M (IgM) and subsequent activation of the complement system and has
been observed in several species [307]. The ABC effect is easily missed
in preclinical research becausemany studies perform single administra-
tion of radiolabelled PEGylated liposomes, use immunodeficientmodels
that cannot mount an IgM response, or use liposomes encapsulating
drugs – such as doxorubicin or oxaliplatin – that are toxic towards the
splenic B cells responsible for anti-PEG IgM production. Recently, the
ABC effect was described with tracer doses of 64Cu-labelled liposomes
in a canine model of spontaneous tumours, which is closer to human
cancer than rodent models are, and in immunocompetent rats [140].
This suggested that using small doses (in terms of lipid amounts) of
radiolabelled liposomes for EPR determination and patient stratification
couldbackfire by suppressing the effect of subsequent administrationsof
liposomal drugs. From the pattern of 64Cu distribution, it appeared that
the accelerated clearance was accompanied by destabilisation of the li-
posomes. Importantly, the study showed that the ABC effect could be
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ing the pool of circulating anti-PEG IgMwith a ‘decoy’ administration of
liposomes 1 h before administration of the actual tracer or drug, and that
the presence of ABC could be detected bymeasuring anti-PEG IgM levels
in blood [140]. Although the role of anti-PEG antibodies is increasingly
recognised [308], the importance of the ABC effect in humans is still
poorly known. In any case, the results from this study will be important
considerations for thedesignof future clinical trials. To illustrate this, any
occurrence of ABC in the 64Cu-MM-302 trial [163] would likely not have
been observed because the radiolabelled liposomeswere administered a
few hours after the therapeutic dose, whichwould presumably have de-
pleted any circulating anti-PEG immunoglobulins. If ABChad occurred to
a significant extent, it is likely that the PET images of 64Cu-MM-302 up-
take would have shown the EPR but not the actual distribution of MM-
302. As a consequence, it may be relevant to screen patients for anti-
PEG immunoglobulins before using PEGylated drugs or radiotracers. An
alternative approach, conceptually similar to the use of humanised anti-
bodies in therapy, may be to use liposomes formed from cell membrane
components with reduced immunogenic potential [82].
Another clinical example of the use of a companion diagnostic for-
mulation for liposomal drugs is given in a study using 99mTc-sulfur col-
loid (TSC) [309]. Palmar-plantar erythrodysesthesia (PPE) is a common
side effect in patients treatedwith liposomal doxorubicin. Under the hy-
pothesis that TSC would be cleared by the RES similarly to liposomal
doxorubicin, the aimwas to predict the occurrence of PPE bymeasuring
the accumulation of TSC in the patients’ hands. A good correlation was
found between TSC levels in the hands and PPE severity, showing TSC
could be used to assess individual RES activity and personalize treat-
ments with liposomal doxorubicin accordingly. An equivalent formula-
tion for PET imaging could be similar to the 64Cu-labelled albumin
described by Rygh et al. [67]. Because these companion diagnostic prod-
ucts do not rely on liposomes for imaging, this approachmight also be a
useful way to circumvent the accelerated blood clearance problem
posed by tracer doses of PEGylated liposomes.
5. Conclusions and perspectives
Nuclear imaging is an important research and clinical tool for track-
ing the biodistribution and pharmacokinetics of liposomal drug delivery
nanocarriers. Comparing the two nuclear techniques available, SPECT is
perhaps themost versatile for preclinical studies due its high spatial res-
olution (compared to preclinical PET scanners), the possibility of using
several well-established radionuclides and chemistries, and the possi-
bility of imaging specific radionuclide pairs simultaneously. This pro-
vides SPECT with the unique ability to track two elements from the
liposomal nanomedicine, such as the phospholipids and the drug
cargo, in vivo. In the clinical setting, however, PET has an advantage
from its superior spatial resolution (compared to clinical SPECT scan-
ners), sensitivity and quantification properties. A frequently highlighted
disadvantage of nuclear imaging is the need for ionising radiation,
which is an important aspect that needs to be considered. It is therefore
essential to have access to expert medical physics and health and safety
teams capable of monitoring and calculating radiation doses. This will
ensure patients and users are safe from unwanted radiation-induced
tissue damage. Recent advances in PET technology, and in particular
total-body PET, are expected to make a significant impact in this field
by allowing whole-body PET imaging of nanomedicines in humans at
lower radiation doses (up to 40x lower) and shorter acquisition times
[310,311].
Our review highlights the importance of choosing the most appro-
priate radionuclide and radiolabellingmethod, as eachwill have advan-
tages and disadvantages. Ideally, the process of radiolabelling a
liposome should result in a product that is stable (both in terms of ra-
diochemical and chemical stability), does not change its overall proper-
ties (e.g.hydrodynamic size, zeta potential), and importantly informs on
its location and concentration in vivowithin the biological lifetimeof theliposome. However, it is important to keep inmind that once in vivo, it is
not possible to use nuclear imaging to directly assess the integrity of the
liposomal drug delivery system, nor the release of the drug cargo. For
example, at late imaging time points when liposomes are more likely
to have been taken up by macrophages, we should expect that the im-
ages represent a mixture of signals from both intact liposomes and the
released radionuclide (still attached or not to its corresponding lipo-
some component, depending on the radiolabelling method) as a result
of liposome degradation. If the aim is to determine the location of the
encapsulated drug rather than the carrier itself, then the preferable op-
tion is to encapsulate a radiolabelled drug, if at all possible. It should be
kept in mind that nuclear imaging does not allow to directly identify
whether the carrier is releasing the drug cargo at the right location.
Thus, we can only obtain indirect measures of both in vivo stability
and drug release kinetics, and in order to do so an understanding and
knowledge of the in vivo behaviour, biodistribution and pharmacokinet-
ics of the free radionuclide and/or radiolabelled liposome component
(e.g. phospholipid or encapsulated drug) are essential. In this context,
the fact that many metallic radionuclide ions and phospholipids share
the same excretion route as liposomes (i.e. hepatic), and even show sig-
nificant tumour uptake (e.g. 64Cu, 68Ga, 111In), complicates the assess-
ment of liposomal in vivo stability and drug release using PET or
SPECT. In contrast, using small metal complexes and radionuclides
with well-defined non-hepatic excretion routes such as 99mTc, 89Zr
and iodide should allow for a clearer distinction between intact lipo-
some and components, and even provide a potential indirect measure
for drug release.
Finally, all the research carried out to date in this field highlights that
liposomal nanomedicines highly benefit from integration with nuclear
imaging techniques. This is particularly important at the clinical stage
where human and disease heterogeneity have been shown to be pres-
ent, and strongly correlated to the target tissue uptake levels and ther-
apeutic efficacy of liposomal nanomedicines. While it may seem at
first glance as an additional layer of complexity and an increased up-
front cost, incorporating nuclear imaging to inform on the in vivobehav-
iour of liposomal nanomedicines from the early developmental stages
to their clinical evaluation stage would help to optimise not only their
translational pathway – for example by providing key information
when clinical trial endpoints are not achieved – but also allow for
imaging-guided personalised nanomedicine treatments. We expect
that by gaining a better understanding of the drug distribution and de-
termining early onwhich patients aremore or less likely to benefit from
a drug, the number of liposomal nanomedicines achieving significant
clinical impact will increase, as well as their clinical efficacy.
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